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ABSTRACT 
ANGELA D. THRASHER: Discrimination, Distrust, and  
Racial/Ethnic Disparities in Antiretroviral Therapy Adherence by HIV+ Patients 
(Under the direction of Jo Anne L. Earp, ScD) 
 
Little is known about the contribution of discriminatory healthcare experiences and 
healthcare provider distrust to racial/ethnic disparities in antiretroviral adherence among HIV+ 
patients. Among participants of the national HIV Cost and Services Utilization Study who 
completed three surveys over 12 months (n = 2267), I examined potential factors associated 
with discriminatory healthcare experiences and healthcare provider distrust. Among participants 
who reported antiretroviral therapy use at the last survey (n = 1911), I used structural equation 
modeling to test direct and indirect relationships among racial/ethnic minority status, 
discriminatory healthcare experiences, healthcare provider distrust, and medication adherence. I 
conceptualized minority status as a proxy for experiences with, and expectations about, racism in 
medicine. Attribution theory and models of antiretroviral therapy adherence informed the 
hypothesized relationships.  
Almost half (41%) the participants reported experiencing discrimination in healthcare 
settings, while few participants reported distrust of their healthcare providers. Factors associated 
with discrimination were being white (an unexpected finding), younger age, some college 
education, earlier HIV diagnosis, poorer self-reported physical health, AIDS diagnosis, ever 
having a CD4 count < 200, any illicit drug use in the past year except heroin or cocaine, and less 
social support. Factors associated with distrust were younger age, some college education, 
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poorer self-reported physical and mental health, higher viral load, drug use in the past year, less 
social support, and more discrimination.  
In the full structural equation model, the direct effect of minority status on adherence 
remained despite the presence of hypothesized mediators. The magnitude of indirect effects via 
discrimination, distrust, and medication efficacy beliefs was negligible, and their sum was not 
statistically significant. The effect of discrimination on adherence was entirely indirect via greater 
distrust and weaker medication efficacy beliefs. Greater distrust was unexpectedly associated 
with better adherence. Distrust indirectly affected adherence via participants’ psychological 
distress about taking antiretroviral therapy and weaker medication efficacy beliefs. These 
findings offer partial support for the relationships posited among experiences and expectations 
of racism (as racial/ethnic minority status), discriminatory healthcare experiences, healthcare 
provider distrust, and antiretroviral therapy adherence. Future researchers should consider 
models with minority status as a contextual influence upon the hypothesized relationships.  
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CHAPTER ONE: 
INTRODUCTION 
 
As research on racial/ethnic disparities in healthcare moves from description to explanation 
(Lurie, 2002), the relationship between healthcare providers and patients has come under greater 
scrutiny. Two landmark reports on the state of the American healthcare system by the Institute 
of Medicine, Crossing the Quality Chasm (Committee on Quality of Health Care in America, 2001) 
and Unequal Treatment (Smedley, Stith, & Nelson, 2003), as well as the Congressionally-mandated 
National Healthcare Disparities Report (Moy, Dayton, & Clancy, 2005), have conclusively 
documented the extent to which members of racial/ethnic minority groups experience poorer 
quality of care compared to whites. On the basis of the now-voluminous evidence, scholars have 
proposed explanations for these disparities that incorporate multiple factors such as racism 
(Gamble, 1997; Jones, 2000; Krieger, 2003; Williams, 1997), stereotyping and bias by physicians 
(Burgess, Fu, & van Ryn, 2004; van Ryn, 2002), miscommunication (Ashton et al., 2003; Cooper, 
Hill, & Powe, 2002; Kagawa-Singer & Kassim-Lakha, 2003), and patient preferences (Katz, 
2001; Rathore & Krumholz, 2004). One pathway recently receiving much attention are the 
attitudes, beliefs, and biases that healthcare providers and racial/ethnic minority patients each 
bring to the clinical encounter. These emotions and opinions likely affect patients’ care-seeking 
behavior, treatment preferences, and compliance with medical recommendations (Balsa & 
McGuire, 2003; Bogart, Bird, Walt, Delahanty, & Figler, 2004; Cooper, 2004; Johnson, Saha, 
Arbelaez, Beach, & Cooper, 2004; Smedley et al., 2003; van Ryn, 2002).  
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Patient perceptions of the way that healthcare providers deliver their services, also known as 
interpersonal care, are among the most proximate factors in the causal chain that explains poorer 
quality care experienced by many racial/ethnic minority groups (Smedley et al., 2003; van Ryn, 
2002). Interpersonal care quality is the extent to which the patient-provider interaction meets or 
exceeds socially defined norms and values, reinforces professional ethics, and matches patients’ 
expectations (Berwick, 2002; Cleary & McNeil, 1988; Donabedian, 1980). In turn, the quality of 
interpersonal care has been shown to influence patients’ healthcare access, patterns of use, and 
outcomes (Berwick, 2002; Brook, McGlynn, & Cleary, 1996; Cleary & McNeil, 1988; 
Donabedian, 1980; Feinstein, 2002). Healthcare providers who are caring and sensitive to patient 
needs, communicate accurately and completely with patients, and consider patient preferences 
when making medical decisions are described as demonstrating high quality interpersonal care, 
also known as greater patient-centeredness (Bethell, 2000; Cleary & McNeil, 1988; Hurtado, 
Swift, & Corrigan, 2001). Healthcare institutions, accreditation boards, and national payers 
routinely use patients’ assessments of interpersonal care in their quality improvement efforts 
(Cleary, 1999; Hurtado et al., 2001; Press, 2002) because “the manner in which care is delivered 
defines, for the patient, the nature and effectiveness of that care” (Press, 2002). 
Racial/ethnic minority patients often report more difficult interactions with their healthcare 
providers than do white patients (Barr, 2004; Collins et al., 2002; Cooper-Patrick et al., 1999; 
Delia, Hall, Prinz, & Billings, 2004; Doescher, Saver, Franks, & Fiscella, 2000; Keating et al., 
2002; LaVeist, Nickerson, & Bowie, 2000; Malat, 2001; Taira et al., 2001). However, few studies 
have explicitly considered poor interpersonal care quality as a predictor of racial/ethnic 
healthcare disparities. In particular, discriminatory healthcare experiences and healthcare provider distrust 
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are two patient-level1 indicators of interpersonal care quality hypothesized as contributing to 
disparate outcomes by racial/ethnic minority status (Boulware, Cooper, Ratner, LaVeist, & 
Powe, 2003; Gamble, 1997; Klassen, Hall, Saksvig, Curbow, & Klassen, 2002; Smedley et al., 
2003). The present study explored discriminatory healthcare experiences and healthcare provider 
distrust in the context of human immunodeficiency virus (HIV) infection, a stigmatizing disease 
that disproportionately affects racial/ethnic minority populations (Centers for Disease Control 
and Prevention, 2006). 
 
1.1. PROBLEM STATEMENT 
The widespread use of antiretroviral therapy in the United States has dramatically reduced 
the morbidity and mortality associated with HIV infection (Centers for Disease Control and 
Prevention, 2002). Attaining the optimal health benefits of this regimen requires near-perfect 
adherence; patients with suboptimal adherence have greater morbidity, are more likely to 
experience treatment failure, and are at higher risk of developing drug resistance (Centers for 
Disease Control and Prevention, 2002). A recent review reported that about half of  
antiretroviral therapy adherence studies that included information about the racial/ethnic make-
up of the sample found that racial/ethnic minority HIV+ patients had poorer adherence than 
white patients (Fogarty et al., 2002). One potential explanation may be unmeasured racial/ethnic 
disparities in interpersonal care quality experienced by HIV+ patients. 
Recent studies suggest that interpersonal care quality is one of many determinants of 
antiretroviral therapy adherence (Bakken et al., 2000; Demmer, 2003; Ingersoll & Heckman, 
2005; Russell, Krantz, & Neville, 2004; Schneider, Kaplan, Greenfield, Li, & Wilson, 2004; van 
                                                 
1 The present study does not directly examine healthcare providers’ actions or intentions (e.g., labeling, stereotyping, 
or bias) that may lead to disparate outcomes and/or may be considered discriminatory (Krieger, 2000; Reidpath et 
al., 2005; Smedley et al., 2003; van Ryn, 2002).  
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Servellen, Chang, Garcia, & Lombardi, 2002). Less is known, however, about the specific 
influence of discriminatory healthcare experiences and healthcare provider distrust on 
antiretroviral therapy adherence, or those attitudes and beliefs about antiretroviral therapy that 
are strong and consistent correlates of adherence. Therefore, the present study examined and 
modeled the relationships among racial/ethnic minority status, discriminatory healthcare 
experiences, healthcare provider distrust, attitudes and beliefs about antiretroviral therapy, and 
antiretroviral therapy adherence using data from a national cohort of HIV+ patients. 
          
1.2. STUDY AIMS 
The aims of the study were:  
• To describe and examine the factors associated with discriminatory healthcare experiences 
and healthcare provider distrust among racial/ethnic minority and nonminority HIV+ 
patients; and 
• To test a causal model of the relationships among racial/ethnic minority status, 
discriminatory healthcare experiences, healthcare provider distrust, antiretroviral therapy 
attitudes and beliefs, and antiretroviral therapy adherence. 
 
1.3. ORGANIZATION OF THE DISSERTATION 
This dissertation consists of six chapters. Chapter Two opens with a brief discussion of how 
interpersonal care quality may be influenced by stigma related to HIV infection and 
race/ethnicity, then reviews the literature on discriminatory healthcare experiences, healthcare 
provider distrust, and antiretroviral therapy adherence. Chapter Three describes the study’s 
conceptual model, presents the research questions, and sets forth the hypotheses to be tested. 
Chapter Four details the study methodology, including research design, sample selection, 
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measurement construction, and analysis plan. Chapter Five presents the results of the analyses. 
Chapter Six summarizes key study findings and makes recommendations for future research and 
practice.  
  
 
 
CHAPTER TWO: 
LITERATURE REVIEW 
 
This chapter presents the conceptual and empirical bases for the present study. The first 
section briefly describes how discriminatory healthcare experiences and healthcare provider 
distrust are the consequences of interpersonal care quality affected by the processes of stigma. 
The next two sections review findings from studies on discriminatory healthcare experiences and 
healthcare provider distrust, two potential consequences of stigma’s effect on interpersonal care 
quality. The final section uses antiretroviral therapy adherence by HIV+ patients as a case study 
of how discriminatory healthcare experiences and healthcare provider distrust might help 
produce racial/ethnic healthcare disparities.  
 
2.1. STIGMA AND INTERPERSONAL CARE QUALITY 
Stigma, which arises from power imbalances within society, degrades interpersonal relations. 
Goffman’s landmark work, Stigma: Notes on the Management of a Spoiled Identity (Goffman, 1963), 
defines stigma as “an attribute that is deeply discrediting within a particular social interaction” (p. 
3). He describes three types: abominations of the body (physical deformities, illnesses); 
blemishes of individual character (e.g., prostitution, substance abuse, mental illness); and tribal 
stigma (race, gender, national origin). Some contemporary scholars have reconceptualized stigma 
as a process rather than a static trait of an individual by incorporating the idea of power 
differentials (Link & Phelan, 2001; Parker & Aggleton, 2003). Link and Phelan argue that the 
stigmatization process begins with members of groups with greater social, political, or economic 
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power labeling an observed difference among members of groups with less power as 
unfavorable (Link & Phelan, 2001). This labeling may then lead to negative stereotyping, 
exclusion, status loss, and discrimination of the labeled individual or group. These types of social 
interaction are perpetrated through such processes as racism, homophobia, classism, ageism or 
sexism (Parker & Aggleton, 2003). The present study focuses on two stigmatized characteristics 
of patients that may negatively affect the clinical encounter: racial/ethnic minority status, a type 
of tribal stigma (Goffman, 1963), and HIV infection, an incurable and threatening disease 
(abomination) that is often the consequence of “deviant” or “immoral” behaviors (blemish).  
2.1.1. Racial/Ethnic Minority Status 
For members of racial/ethnic minority groups, stigma manifests as various forms of racism. 
Jones describes three levels of racism: institutionalized racism, the differential access to power 
and resources by racial/ethnic minority status; personally-mediated racism, the prejudice and 
discrimination of individuals that is most commonly thought of as “racism”; and internalized 
racism, the negative self-worth exhibited by members of stigmatized races because of their 
acceptance of negative messages about their groups’ abilities and worth(Jones, 2000). These 
different manifestations of racism directly and indirectly affect an individual’s health. One 
pathway is through the experience of “inadequate or degrading” medical care (Krieger, 2003).  
Concerns by members of racial/ethnic minority groups about the inequitable provision of 
care due to racism have their roots in historical, as well as present-day, experiences with the U.S. 
healthcare system (Corbie-Smith, 1999; Gamble, 1997; Jones, 2001; LaVeist, 1994; Williams, 
1997). The Tuskeegee Syphilis Study is infamous (Jones, 1993), but the legally-entrenched racial 
segregation and disparate treatment that were in place until the passage of the Civil Rights Acts 
of 1964 (Smith, 2005) arguably had more pervasive effects on racial/ethnic minorities’ attitudes 
about the healthcare system. The effects likely happened through both personal experiences and 
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beliefs about racism in medical care transmitted through social networks. For these reasons, 
racial/ethnic minority status may act as a proxy for beliefs, experiences, and expectations about 
racism in healthcare (LaVeist, 1994; Williams, 1997).  
2.1.2. HIV Infection 
HIV/AIDS seemingly came out of nowhere in the early 1980s, initially spreading quickly 
through largely unknown modes of transmission and considered an almost certain death 
sentence (Shilts, 1987). The disease was primarily associated with members of already-
stigmatized groups such as homosexuals, injection drug users, and sex workers. Infants and 
individuals who were infected through blood transfusions, on the other hand, were considered 
innocent victims. The stigma of infection is thus bound to other stigmatized practices and 
personal characteristics (Reidpath & Chan, 2005). These characteristics of communicability, 
lethality, and association with other stigmatized groups mean that HIV/AIDS evokes powerful 
stigma (Herek et al., 1998; Madru, 2003; Reidpath & Chan, 2005; Weiner, Perry, & Magnusson, 
1988).  
People living with HIV/AIDS must contend with pervasive stigma and bias among the 
general population (Herek & Capitanio, 1993; Herek, Capitanio, & Widaman, 2002; Herek & 
Glunt, 1988). Studies conducted throughout the more than 25-year course of the epidemic 
consistently show that a substantial proportion of the general public feel that those infected with 
HIV “deserve” their illness, express discomfort being around those with the disease, and hold 
inaccurate beliefs about how the virus is spread (Centers for Disease Control and Prevention, 
2000; Herek et al., 2002). Early studies found similar beliefs existed among some healthcare 
providers (Forrester & Murphy, 1992; Gerbert, Maguire, Bleeker, Coates, & McPhee, 1991; 
McCann, 1997; Robinson, 1998). The stigma experienced by people living with HIV/AIDS leads 
to physical and emotional trauma, indirectly promotes disease transmission, limits access to care, 
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and provides a barrier to self-care behaviors such as medication adherence (Madru, 2003; 
Sandelowski, Lambe, & Barroso, 2004; Taylor, 2001; UNAIDS, 2002). 
2.1.3. The Effects of Stigma in the Clinical Encounter 
Stigma arising from racial/ethnic minority and HIV status, among others, may produce 
poorer quality interpersonal care by affecting the attitudes, beliefs, and behaviors of healthcare 
providers and patients. Healthcare providers may have conscious or unconscious biases about 
patients with stigmatizing characteristics. In turn, these biases may affect providers’ clinical 
decision-making or pattern of referrals (Reidpath & Chan, 2005; Smedley et al., 2003; van Ryn, 
2002). HIV+ patients who are injecting drug users, for example, may receive less than optimal 
care from healthcare providers who hold negative stereotypes about people diagnosed with 
HIV/AIDS or who are injecting drug users, or both (Ding et al., 2005; Ware, Wyatt, & 
Tugenberg, 2005). Patients with stigmatizing characteristics may be more likely than those 
without such characteristics to perceive unfair treatment by healthcare providers (or discriminatory 
healthcare experiences) and have lower expectations that providers will act in their best interests (or 
healthcare provider distrust). These attitudes, in turn, may influence patients’ health-related behaviors 
such as medication adherence (Bogart et al., 2004; Smedley et al., 2003). The following sections 
describe these patient-level processes and pathways in further detail.  
 
2.2. DISCRIMINATORY HEALTHCARE EXPERIENCES 
As they do with other problematic healthcare experiences (Cleary, 1999; Edgman-Levitan & 
Cleary, 1996; Gerteis, Edgman-Levitan, Daley, & Delbanco, 1993), patients identify discriminatory 
healthcare experiences through a process of awareness and interpretation of providers’ behaviors. 
Discriminatory healthcare experiences are related to beliefs about healthcare bias or medical 
racism, global beliefs about the inequitable provision of care (LaVeist et al., 2000), but are based 
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on specific interactions patients have or have had with particular healthcare providers. Patients 
consider unfair acts or poor treatment by healthcare providers to be discriminatory when these 
acts are attributed to patients’ memberships in stigmatized groups (Bird & Bogart, 2001; Bird, 
Bogart, & Delahanty, 2004; Krieger, 1999; Lillie-Blanton, Brodie, Rowland, Altman, & 
McIntosh, 2000; Schuster et al., 2005). This section presents a theoretical framework for 
understanding why patients may or may not perceive discriminatory healthcare experiences, as 
well as what is known about individual-level antecedents and consequences of discrimination in 
healthcare settings.  
2.2.1. Attribution and Ambiguity in the Clinical Encounter 
Attributions, individual perceptions of what causes others’ behaviors, and the consequences 
of those perceptions are well-established phenomena within social psychology research. 
Attributions can be formed through deliberate reflection or without conscious thought, and are 
shaped by information, beliefs, and motivation (Kelley & Michela, 1980). In turn, attributions 
may influence an individual’s behaviors, emotions, and expectancies about future events (Harvey 
& Weary, 1984; Kelley & Michela, 1980). The process is not strictly linear, as the consequences 
of attribution become the antecedents of future judgments about causation (Kelley & Michela, 
1980).  
Attribution theory suggests that perceptions of discriminatory healthcare experiences are 
formed through the interactions between healthcare providers and patients’ attitudes and 
behaviors. Many researchers believe that healthcare providers in general are not actively 
prejudiced against members of racial/ethnic minority groups (Ashton et al., 2003; Burgess et al., 
2004; Smedley et al., 2003; van Ryn, 2002). Rather, discrimination may flow from more subtle 
processes: greater clinical uncertainty during encounters with minority patients; stereotypes 
about the health behaviors of minority patients; or greater difficulty in communicating with 
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minority patients (Ashton et al., 2003; Burgess et al., 2004; Smedley et al., 2003; van Ryn, 2002). 
Provider behaviors that patients may interpret as discriminatory range in their degree of 
ambiguity from those that are extreme and overtly manifest to those so subtle that their 
existence relies solely on an individual’s judgment (Bird & Bogart, 2001; Schuster et al., 2005). 
Relatively unambiguous expressions of provider discrimination include treatment refusal or 
overt expressions of hostility. Healthcare providers’ subtle expressions of discomfort or 
difficulties in communication may be interpreted as discrimination if patients believe that the 
problems are attributed to the patients’ membership in stigmatized groups. The greater the 
ambiguity about healthcare providers’ intentions, the more that perceptions of provider’s 
behavior as discriminatory rely on patients’ beliefs, motivations, and background experiences.  
Once perceived, members of stigmatized groups must assess whether negative feedback 
received from members of non-stigmatized groups is valid, the result of bias, or represents other 
processes unrelated to bias, such as uncertainty or misinformation (Crocker & Major, 1989). 
Factors that may lead individuals to report discrimination in ambiguous contexts include: past 
experiences with discrimination, the desire to protect self-esteem or, at the extreme, 
hypervigilence (Allport, 1954; Crocker & Major, 1989; Pinel, 1999). Factors that may depress 
reporting of discrimination include fear of reprisals or being labeled by others as a troublemaker, 
a complainer, or paranoid; perception of greater discrimination against one’s group than oneself; 
or, at the extreme, internalized stigma (Ruggiero & Taylor, 1995; Schnittker & McLeod, 2005; 
Sechrist, Swim, & Stangor, 2004; Stangor, Swim, Van Allen, & Sechrist, 2002; Taylor, Wright, 
Moghaddam, & Lalonde, 1990). Given these complexities when intentions and actions are 
ambiguous, it can be difficult to determine what is motivating a particular individual to report (or 
not report) discrimination (Ruggiero & Taylor, 1995).  
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2.2.2. Prevalence 
Research suggests that up to one in five individuals report discriminatory healthcare 
experiences (Lillie-Blanton et al., 2000; Perez, 2005; Piette, Bibbins-Domingo, & Schillinger, 
2006). For example, a national study found that Asians (20%), Hispanics (19%), and African 
Americans (14%) were more likely than whites (9%) to report being treated with disrespect or 
being looked down upon by their healthcare provider in the past two years (Lillie-Blanton et al., 
2000). One study of a representative sample of non-institutionalized adults in California, 
however, found that only approximately 5% reported feeling discriminated against when 
receiving healthcare in the past year, ranging from 2.9% for Asians to 8.8% for American 
Indians (Trivedi & Ayanian, 2006). Issues of attribution and ambiguity, as well as access to care, 
may affect prevalence estimates of discriminatory healthcare experiences. The reported 
attributions made by members of racial/ethnic minority groups for discriminatory healthcare 
experiences are not exclusively, or even predominantly, related to racial/ethnic identity (Bird & 
Bogart, 2001; Lillie-Blanton et al., 2000; Piette et al., 2006; Trivedi & Ayanian, 2006). 
Discrimination in healthcare settings may be attributed to stigmatized characteristics other than 
racial/ethnic minority status, such as income level or insurance status (Lillie-Blanton et al., 
2000), drug use behaviors (Ding et al., 2005; Ritson, 1999), same-gender sexual orientation 
(Hayter, 1996; Klitzman & Greenberg, 2002; Malebranche, Peterson, Fullilove, & Stackhouse, 
2004), or HIV status (Cobb & De Chabert, 2002; Knussen & Niven, 1999; Robinson, 1998). 
These findings support the idea of stigma “layering,” where multiple characteristics contribute to 
the effect of stigma on an individual (Reidpath & Chan, 2005).  
The few studies that have measured the extent of discriminatory healthcare experiences 
among HIV+ patients do not find the same pattern of differences by racial/ethnic minority 
status as in the general population. Overall a quarter (26%) of the participants in the HIV Cost 
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and Services Utilization Study (HCSUS) conducted between 1996 and 1997, the data used for 
the present study, reported ever experiencing at least one of four types of discriminatory 
healthcare experiences (Schuster et al., 2005). Participants were asked whether any healthcare 
provider had ever been uncomfortable with them, treated them as inferior, preferred to avoid 
them, or refused them service since they had become HIV+; the perceived causes of this 
treatment were not reported. The most common response was that a healthcare provider had 
been uncomfortable with them (26%). White patients were more likely than other groups to 
report ever having at least one discriminatory healthcare experience. Possible explanations for 
this unexpected result include underreporting of discriminatory healthcare experiences by 
racial/ethnic minority patients or their selection of more welcoming healthcare settings (Schuster 
et al., 2005).  
A later study, using a smaller convenience sample but a larger pool of items to measure 
discriminatory healthcare experiences, found a much higher prevalence of discriminatory 
experiences among participants recruited through one Midwestern AIDS service organization 
(Bird et al., 2004).  Participants reported whether and how often (in qualitative, not numeric, 
terms) healthcare providers showed them less courtesy than other patients, acted afraid of them, 
and did not listen to them because of either their racial/ethnic minority or socioeconomic status. 
Discrimination scores did not vary by racial/ethnic minority status. The majority of participants 
(71%) reported ever suffering at least one of seven specific discriminatory experiences because 
of their race or socioeconomic status, and a quarter of the sample (26%) reported all seven 
types. The most common response attributed to both racial/ethnic and socioeconomic status 
was that a doctor or nurse did not listen to what the patient said (57%). While the lifetime 
prevalence of discriminatory healthcare experiences was high, participants reported that these 
experiences did not happen frequently. These studies suggest that, for HIV+ patients, the 
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prevalence of less ambiguously negative acts, such as treatment refusal, are much lower than are 
the more subtle difficulties experienced during patient-provider interactions. They also remind 
us that individuals may attribute such perceived discrimination to a number of stigmatized 
characteristics, such as an HIV infection, racial/ethnic minority status, or low socioeconomic 
status.  
2.2.3. Antecedents and Consequences of Discriminatory Healthcare Experiences 
Little is known about what factors are associated with reporting of discriminatory healthcare 
experiences. In unadjusted bivariate analyses, diabetic patients who reported discriminatory 
healthcare experiences were more likely to be members of racial/ethnic minority groups, female, 
and have lower annual income (Piette et al., 2006). Another exploratory study among African 
American adults found that higher educational attainment and stronger expectations of 
stereotyping by physicians were associated with discriminatory healthcare experiences (Bird & 
Bogart, 2001). Research among HIV+ patients suggests different correlates. An early study 
among homosexual and bisexual men in a clinical trial found that more advanced HIV infection 
was associated with more treatment refusals, which participants believed were based on their 
HIV status (Kass, Faden, Fox, & Dudley, 1992). Serostatus was the only characteristic 
considered by the researchers as a potential cause of discrimination, and results were not 
analyzed by racial/ethnic minority status. A later study found that discriminatory healthcare 
experiences were associated with depression, more AIDS-related symptoms, poor general health, 
and less satisfaction with the healthcare received (Bird et al., 2004). Both this and the previous 
study, however, only reported unadjusted bivariate associations. In multivariate analyses, 
Schuster and colleagues (2005) found that discriminatory healthcare experiences reported by 
participants in the HIV Cost and Services Utilization Study were independently associated with 
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being white, having greater than a high school education, having any health insurance other than 
private, and being diagnosed with HIV for a longer period of time.  
Most studies find discriminatory healthcare experiences to be inversely associated with 
healthcare outcomes such as service use and health behaviors. This is consistent with attribution 
theory, which finds that perceptions of others’ behaviors may influence one’s own emotions, 
expectations, and behaviors. Discriminatory healthcare experiences have been independently 
associated in cross-sectional research with: greater numbers of hospital visits in the past year 
(Bird & Bogart, 2001); reduced likelihood of receiving age- and disease-appropriate preventive 
care (Trivedi & Ayanian, 2006); delay in filling pharmacy refills (Van Houtven et al., 2005); and 
less compliance with physician recommendations (Blanchard & Lurie, 2004). The two studies 
that have examined the consequences of discriminatory health experiences reported by HIV+ 
patients, one of which uses data considered in the present study, find associations with poorer 
access to care (Schuster et al., 2005) and lower ratings of medical care (Bird et al., 2004; Schuster 
et al., 2005). Previous studies have only examined the direct effect of discriminatory healthcare 
experiences on patient outcomes. Although some research suggests that discriminatory 
healthcare experiences are related to both treatment experience and treatment-related beliefs 
(Bird et al., 2004; Piette et al., 2006), no study to date has explicitly examined whether 
discriminatory healthcare experiences indirectly influence patient-level outcomes through 
treatment-related attitudes and beliefs.  
 
2.3. HEALTHCARE PROVIDER DISTRUST 
Interpersonal trust, a fundamental aspect of the patient-provider relationship, reflects 
patients’ expectations that their healthcare providers will act in their best interests (Goold, 2002; 
Hall, Camacho, Dugan, & Balkrishnan, 2002; Thom, Hall, & Pawlson, 2004). Longstanding 
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paradigms in medical sociology describe the patient-provider relationship as asymmetrical but 
reciprocal, with each side having different expectations and responsibilities, as patients cede a 
degree of power to their healthcare providers when ill (Freidson, 1996; Parsons, 1951; Wolinsky, 
1980). This asymmetry means that patients must evaluate to the extent possible providers’ 
intentions, character, or values if they are to trust providers to work on their behalf (Goold, 
2002; Parsons, 1951). Healthcare provider distrust occurs when patients’ expectations that their 
providers will act in their best interests are not met. It differs from generalized distrust of the 
healthcare profession, institution, and payers because distrust is based on specific experiences 
with a particular provider (Goold, 2002; Keating et al., 2002; Pearson & Raeke, 2000). This 
section describes the factors that influence patients’ trust in their healthcare provider, examines 
the level of healthcare provider distrust among patients with and without HIV infection, and 
summarizes the individual-level antecedents and consequences of healthcare provider distrust. 
2.3.1. Domains of Trust 
 Patients’ feelings of trust are based on holistic assessments of a provider’s technical 
competency, interpersonal competency, agency, and confidentiality (Hall et al., 2002; Pearson & 
Raeke, 2000; Thom et al., 2004). Technical competency is the extent to which patients believe 
that providers have the requisite skills and use these appropriately. Interpersonal competency 
refers to patient assessments of provider communication and relationship-building skills. Agency 
means that patients expect their providers to act in their best interests, putting patients’ health 
above cost or other considerations, such as research needs. Confidentiality, although included as 
a domain of interpersonal trust in some studies, appears to be a less important determinant 
among the general population (Hall et al., 2002; Thom & Campbell, 1997) but it may have 
increased relevance for patients living with HIV/AIDS or other stigmatizing illnesses (Hall et al., 
2002; Roberts, 2002; Stone et al., 1998). These conceptual distinctions notwithstanding, 
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psychometric analyses of validated multi-item trust scales (Anderson & Dedrick, 1990; Kao, 
Green, Davis, Koplan, & Cleary, 1998; Safran et al., 1998) indicate that patients’ assessment of 
any one domain of interpersonal trust affects their evaluation of all domains (Pearson & Raeke, 
2000; Thom et al., 2004). Conversely, the multiple domains offer multiple ways for interpersonal 
trust of healthcare providers to be breached and distrust to occur. 
2.3.2. Levels of Trust and Distrust 
Distrust of individuals’ own providers is relatively low (Balkrishnan, Dugan, Camacho, & 
Hall, 2003; Blendon & Benson, 2001; Kao et al., 1998; Safran et al., 1998) compared to distrust 
of the healthcare profession, institutions, and payers in general (Gamble, 1997; Goold, 2002; 
Kao, Green, Zaslavsky, Koplan, & Cleary, 1998; Kronenfeld, 2001). For example, Hall and 
colleagues (2002) found that, on average, trust in a specific physician was approximately 28% 
higher than global trust in physicians as a profession. African Americans and members of other 
racial/ethnic minority groups, however, generally report lower levels of trust in their own 
physicians than do whites (Boulware et al., 2003; Corbie-Smith, Thomas, & St George, 2002; 
Doescher et al., 2000; Schnittker, 2004; Taira et al., 2001), as well as less trust of physicians and 
the healthcare system in general (Brandon, Isaac, & LaVeist, 2005; LaVeist et al., 2000; Rose, 
Peters, Shea, & Armstrong, 2004). 
As with the general population, studies of HIV+ patients report high levels of trust by these 
patients in their own healthcare providers (Altice, Mostashari, & Friedland, 2001; Brandon et al., 
2005; Golin et al., 2002; Ingersoll & Heckman, 2005; Schneider et al., 2004; Whetten, Leserman, 
Whetten, & et al., 2006). For example, the average healthcare provider trust score in a large, 
cross-sectional study of HIV+ patients in the metropolitan Boston area was 84.8 on a 100-point 
scale (SD = 13.9), with almost a quarter of the sample at the ceiling (Schneider et al., 2004). 
Similarly, HIV+ patients at a university-based clinic in California averaged 4.5 on a 5-point scale 
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of trust in personal physician (Golin et al., 2002). Unlike the general population, HIV+ patients’ 
trust in their own healthcare provider did not vary by racial/ethnic minority status (Altice et al., 
2001; Golin et al., 2002; Whetten et al., 2006).  
2.3.3. Antecedents and Consequences of Healthcare Provider Distrust 
Many antecedents of healthcare provider distrust have been investigated, though not among 
HIV+ patients. Greater healthcare provider distrust is associated with racial/ethnic minority 
status (Boulware et al., 2003; Corbie-Smith et al., 2002; Doescher et al., 2000; Schnittker, 2004; 
Taira et al., 2001), lower annual income (Schnittker, 2004), not having a usual healthcare 
provider (Doescher et al., 2000), poorer health status (Doescher et al., 2000), and less education 
(Schnittker, 2004). Most previous studies of HIV+ patients, however, have not explored 
potential antecedents of healthcare provider distrust beyond racial/ethnic minority status. The 
present study explored sociodemographic, health, psychosocial, and service use factors 
associated with healthcare distrust by HIV+ patients. 
One potential psychosocial factor is discriminatory healthcare experiences. Each interaction 
within a clinical encounter helps to shape patients’ expectation of future care (Goold, 2002; 
Keating et al., 2002), and thus past discriminatory healthcare experiences may increase patients’ 
healthcare provider distrust. Some indirect evidence of an association between discriminatory 
healthcare experiences and healthcare provider distrust can be found in research examining the 
relationship between problematic healthcare experiences and healthcare provider distrust. 
Among respondents enrolled in managed care plans in three metropolitan areas, for example, 
each problematic experience (e.g., physicians did not always give understandable answers to 
questions or involve patients in decisions as much as desired) was associated with lower trust in 
personal physicians after controlling for both trust in the health plan and general trust in others, 
as well as other sociodemographic and care characteristics (Keating et al., 2002). Only two 
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studies to date, however, have directly examined the potential relationship between healthcare 
provider distrust and discriminatory healthcare experiences. Using the same dataset as does the 
present study, Schuster and colleagues (2005) found that HIV+ patients who reported ever 
experiencing healthcare discrimination trusted their current doctor less than those who did not 
report experiencing any discrimination, even after controlling for respondent characteristics. Past 
poor treatment by doctors reported by HIV+ inmates in a Connecticut prison was associated 
with greater healthcare provider distrust (Altice et al., 2001). The few studies that have examined 
the relationship between healthcare provider distrust and behavioral outcomes find lower 
compliance with physician recommendations among the general population (Safran et al., 1998; 
Thom & Campbell, 1997) and greater delay in initiating care by HIV+ patients in the HIV Cost 
and Services Utilization Study (Turner et al., 2000). Previous research has not explored the 
extent to which healthcare provider distrust influences the treatment-related attitudes and beliefs 
that directly affect patient-level behavioral outcomes. Therefore, the present study examined the 
direct and indirect effects of discriminatory healthcare experiences and healthcare provider 
distrust on antiretroviral therapy adherence, a critical behavioral outcome for HIV+ patients. 
 
2.4. DISCRIMINATORY HEALTHCARE EXPERIENCES, HEALTHCARE PROVIDER 
DISTRUST, AND ANTIRETROVIRAL THERAPY ADHERENCE BY HIV+ PATIENTS 
 
Antiretroviral therapy, which produced dramatic reductions in HIV/AIDS morbidity and 
mortality after its introduction in 1996 (Centers for Disease Control and Prevention, 2003), 
requires near-perfect and lifelong adherence to produce optimal health benefits (Palella et al., 
1998; Paterson et al., 2000). Antiretroviral therapy adherence means not missing any doses of 
prescribed medication (Chesney, 2000). This patient-controlled outcome often varies by 
racial/ethnic minority status, with racial/ethnic minority HIV+ patients having poorer 
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adherence than white patients (Gifford et al., 2000; Golin et al., 2002; Gordillo, del Amo, 
Soriano, & Gonzalez-Lahoz, 1999; van Servellen et al., 2002; Wenger et al., 1999). Few 
researchers, however, have explicitly considered potential mediators, such as discriminatory 
healthcare experiences or healthcare provider distrust, of the relationship between racial/ethnic 
minority status and antiretroviral therapy adherence. The following section presents an overview 
of antiretroviral therapy adherence and its determinants, and also examines the potential role of 
discrimination and distrust in producing racial/ethnic disparities in antiretroviral therapy 
adherence.  
2.4.1. Antiretroviral Therapy and the Importance of Adherence 
Of the approximately 529,000 people in the United States living with HIV/AIDS in 2002, 
over 80% had been prescribed antiretroviral therapy2, 3 (Centers for Disease Control and 
Prevention, 2003). Regimens consist of two or more antiretroviral agents from three different 
drug classes (protease inhibitors, nonnucleoside reverse transcriptase inhibitors, and nucleoside 
reverse transcriptase inhibitors); Highly Active Anti-Retroviral Therapy (HAART) is a specific 
combination of medications that is considered the gold standard of HIV/AIDS care (Centers 
for Disease Control and Prevention, 2002). Many antiretroviral therapy regimens require 
multiple pills at multiple dosing intervals with specific food requirements and may cause a 
number of adverse side effects, such as diarrhea, nausea, and vomiting (Centers for Disease 
                                                 
2 Use of antiretroviral therapy is lower among racial/ethnic minority HIV+ patients, especially African Americans, 
even after controlling for health status, access to healthcare services, and sociodemographic variables (Crystal et al., 
2001; Gebo et al., 2005; Palacio et al., 2002; Wong et al., 2003). Access to antiretroviral therapy – and thus the 
potential for adherence – implies the existence of a source of care, joint provider-patient decision making regarding 
its use, and an expectation of regular follow-up care (Giordano, 2006). To the extent that discriminatory healthcare 
experiences and healthcare provider distrust play a role in actual access to and use of antiretroviral therapy (which is 
largely unknown), the present study considers these factors as a potential source of selection bias as well as potential 
determinants of adherence.  
 
3 The data used in the present study was collected between 1996 and 1997. The Centers for Disease Control and 
Prevention (1997) reported that 641,086 individuals were living with AIDS by December 1997. The previous year 
had witnessed a 25% reduction in deaths from AIDS-related illnesses, the first time in the United States epidemic, 
attributed to the increased use of antiretroviral therapy (CDC, 1997). 
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Control and Prevention, 2002). The treatment prolongs life by reducing patients’ viral loads to 
undetectable levels (<50 copies/mL). High levels of HIV impair the immune system and lead to 
the opportunistic infections characteristic of an AIDS diagnosis. HIV+ patients must take at 
least 95% of prescribed medication every day for the rest of their lives to maintain life-
prolonging viral suppression (Paterson et al., 2000). 
No matter how it is measured (e.g., patient self-report, pill counts, pharmacy records, HIV 
viral load, electronic pill cap monitors, or a combination) however, poor adherence to 
antiretroviral therapy is common. Studies suggest that up to half of HIV+ patients who are 
prescribed antiretroviral therapy do not consistently adhere to their medication directions 
(Deeks et al., 1999; Lucas, Chaisson, & Moore, 1999). This estimate is similar to medication 
adherence rates for other chronic diseases (McDonald, Garg, & Haynes, 2002; Sackett & 
Haynes, 1976). In the case of antiretroviral therapy, however, those who miss even a few doses 
may see steep declines in immune system functioning, and consequently face a greater likelihood 
of HIV/AIDS-related morbidity and mortality (Lucas et al., 1999; McNabb et al., 2001; 
Montaner et al., 1996; Palella et al., 1998; Paterson et al., 2000; Powderly et al., 1999; Valdez et 
al., 1999). In addition, inconsistent medication use may encourage the development of drug-
resistant strains of HIV (Durant et al., 1999; Sethi, Celentano, Gange, Moore, & Gallant, 2003). 
Improving antiretroviral therapy adherence is thus a major strategy for reducing the impact of 
the HIV/AIDS epidemic (Amico et al, 2006; Giordano, 2006).  
2.4.2. Determinants of Antiretroviral Therapy Adherence 
The reasons for poor adherence to antiretroviral therapy are multiple and complex (Chesney, 
2003; Ickovics & Meade, 2002). Patients commonly report forgetfulness, being busy, being away 
from home, changing daily routine, experiencing medication side effects, and being depressed or 
ill as barriers to adherence (Chesney, 2003). Drawing upon the treatment adherence literature for 
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chronic diseases and empirical studies of HIV+ patients, Ickovics and Meade (2002) proposed a 
model that considers antiretroviral therapy adherence to be the result of the dynamic interplay of 
multilevel factors. Patient factors include knowledge of the disease and treatment regimen, 
health beliefs about the disease and treatment, perceptions (e.g., perceived threat of illness and 
perceived benefits of treatment), self-efficacy regarding one’s ability to adhere, coping skills, and 
stress. Treatment regimen factors include the existence and severity of side effects, as well as the 
complexity of the treatment regimen. Socioenvironmental factors include availability of social 
support and access to care. Practioner factors include patient-provider communication patterns, 
the nature of the relationship with the provider, and the level of patient participation in medical 
decision-making – all of which are components of interpersonal care quality.    
High quality interpersonal care may facilitate adherence to antiretroviral therapy adherence. 
Better adherence is associated with different measures of interpersonal care such as greater 
satisfaction with care (Russell et al., 2004; Schneider et al., 2004), higher engagement with 
healthcare providers (Bakken et al., 2000; Demmer, 2003), better treatment by clinic staff (van 
Servellen et al., 2002), and better physician-patient relationship quality (Ingersoll & Heckman, 
2005; Schneider et al., 2004). These findings are supported by qualitative studies of antiretroviral 
therapy adherence (Laws, Wilson, Bowser, & Kerr, 2000; Malcolm, Ng, Rosen, & Stone, 2003; 
Roberts, 2002; Stone et al., 1998), and complement research on adherence and patient-provider 
interactions conducted in the pre-HAART era of HIV/AIDS care (Stall et al., 1996).  
2.4.3. Discrimination, Distrust, and Antiretroviral Therapy Adherence 
Less is known, however, about the extent to which discriminatory healthcare experiences 
and healthcare provider distrust influence adherence to antiretroviral therapy. Only one study to 
date has examined the relationship between discriminatory healthcare experiences and 
antiretroviral therapy adherence. Among clients of a Midwestern AIDS service organization, 
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perceived discrimination that was attributed to socioeconomic status, but not race, was 
negatively associated with medication adherence (Bird et al., 2004). In terms of distrust, the 
process of negotiation with healthcare providers may influence compliance with medical 
recommendations (Carr, 2001). Previous studies, which examine the issue in terms of trust rather 
than distrust, find some support for that view. Trust in one’s physician was independently 
associated with self-reported antiretroviral therapy adherence in a large, cross-sectional study of 
HIV+ patients in the Boston area (Schneider et al., 2004). Another study found that trust was 
significantly associated with acceptance of and adherence to antiretroviral therapy among 
participants in a prison-based, directly-observed therapy program (Altice et al., 2001), although 
the sample and setting reduces generalizability to the broader population of HIV+ patients. In 
contrast, trust was not associated in multivariate analyses with a composite adherence measure in 
a prospective study of Los Angeles county HIV clinic patients (Golin et al., 2002).  
The relative lack of information in this area makes it difficult to determine whether, and if so 
how, discriminatory healthcare experiences and healthcare provider distrust negatively influence 
antiretroviral therapy adherence by HIV+ patients. As with research using other measures of 
interpersonal care quality, the combination of convenience sampling and small sample sizes used 
in many studies increases the possibility of selection bias and threatens the validity of the 
findings. In addition, existing research has only examined the direct effects of discriminatory 
healthcare experiences and healthcare provider distrust on antiretroviral therapy adherence. 
HIV+ patients’ beliefs about and attitudes toward antiretroviral therapy are some of the most 
consistent and proximate determinants of adherence (Chesney, 2003; Ickovics & Meade, 2002; 
Richter, Sowell, & Pluto, 2002; Viswanathan, Anderson, & Thomas, 2005). Negative feelings 
towards healthcare providers that manifest as, or result from, discriminatory healthcare 
experiences and healthcare provider distrust may lead HIV+ patients to doubt the efficacy and 
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worth of antiretroviral therapy, and thus make them less likely to adhere to their prescribed 
medication.  
2.4.4. Does Racial/Ethnic Minority Status Play a Role? 
Racial/ethnic minority status is inconsistently associated with antiretroviral therapy 
adherence by HIV+ patients. Many studies find that racial/ethnic minority patients have poorer 
adherence than white patients (Gifford et al., 2000; Golin et al., 2002; Gordillo et al., 1999; van 
Servellen et al., 2002; Wenger et al., 1999), while others show no difference (Paterson et al., 
2000; Wutoh et al., 2001). The relationship between racial/ethnic minority status and 
antiretroviral therapy adherence sometimes disappears after controlling for key predictors of 
adherence such as depression, active alcohol and drug use, or low health literacy (Stone, 2006). It 
is worth asking, however, what racial/ethnic minority status may be acting as a proxy for when 
an association is observed, as well as what factors may explain such a relationship.  
Existing research on antiretroviral therapy adherence and interpersonal care quality has not 
specifically investigated racial/ethnic differences, and studies generally have not been designed 
to detect moderate or small effects. Research that is not specifically conceptualized or designed 
to make comparisons by racial/ethnic minority status may come to erroneous post hoc 
conclusions about the meaning of both significant and nonsignificant study findings (Corbie-
Smith, Moody-Ayers, & Thrasher, 2004; Kagawa-Singer, 2000; LaVeist, 1994). Indeed, studies 
on interpersonal care quality and antiretroviral therapy adherence seldom report analyses by 
racial/ethnic group. The only published study with a large, diverse sample that examined 
racial/ethnic differences in the quality of interpersonal HIV/AIDS care and self-reported 
antiretroviral therapy adherence found no differences in quality or adherence (Bakken et al., 
2000; Wilson, 2005). Unpublished analyses in another study with a large, diverse sample also 
found no racial/ethnic differences in either interpersonal care quality or antiretroviral therapy 
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adherence (Schneider et al., 2004; Wilson, 2005). However, neither study incorporated measures 
of discriminatory healthcare experiences nor did they consider the potential indirect effects of 
interpersonal care quality on antiretroviral therapy adherence. 
The present study considered racial/ethnic minority status as a crude indicator of patients’ 
beliefs, experiences, and expectations about racism in healthcare. Following attribution theory, 
experiencing discrimination from healthcare providers and/or having greater distrust in one’s 
own healthcare provider may reduce the likelihood that racial/ethnic minority HIV+ patients 
comply with treatment. Furthermore, experiences and expectations of racism in healthcare 
settings may increase the skepticism and lack of confidence some racial/ethnic minority HIV+ 
patients have in the treatments that are offered. To date, however, no study has explored 
whether and how discriminatory healthcare experiences and healthcare provider distrust affect 
patients’ attitudes and beliefs about antiretroviral therapy. Therefore, the present study used data 
from a large, multiethnic cohort of HIV+ patients to specifically examine the relationships 
among racial/ethnic minority status, discriminatory healthcare experiences, healthcare provider 
distrust, attitudes and beliefs about antiretroviral therapy, and adherence.  
 
 
 
 
 
CHAPTER THREE:  
CONCEPTUAL MODEL, RESEARCH QUESTIONS,  
AND HYPOTHESES 
 
 
The theoretical perspectives and empirical findings on discrimination, distrust, and 
antiretroviral therapy adherence described in Chapter 2 informed the conceptual model for the 
present study. This chapter defines the constructs in that model and their relationships with each 
other, as well as sets forth the study research questions and hypotheses.  
 
3.1. CONCEPTUAL MODEL 
3.1.1. Definitions 
Racial/ethnic minority status refers to an individual’s self-classification in the United States into 
one of the Office of Management and Budget categories other than Caucasian: African 
American; Hispanic ethnicity (any race); American Indians or Native American; Asian American; 
Pacific Islander and Native Hawaiian. Self-classification in multiple categories is also possible 
(Mays, Ponce, Washington, & Cochran, 2003). Many researchers have described racial/ethnic 
minority designation in the United States as representing a subordinate social status. The 
designation often serves as a proxy for lower socioeconomic position, having less education, 
“different” (non-majority) cultural practices, a history of oppression, or experience of 
discrimination (Krieger, 1999; LaVeist, 1994; Williams, 1997). In the present study, racial/ethnic 
minority status is conceptualized as a proxy for beliefs, experiences, and expectations about 
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racism in healthcare, including general distrust of the healthcare system (Gamble, 1997; LaVeist, 
1994; Williams, 1997). 
Discriminatory healthcare experiences refer to perceived unfair acts or poor treatment by 
healthcare providers toward members of lower status socially-defined groups such as 
racial/ethnic minorities (Krieger, 1999). This definition assumes that individuals accorded such 
treatment perceive the unfairness as a type of discrimination attributable to their subordinate 
status in a hierarchical society.  
Healthcare provider distrust is the negative expectation held by patients of their providers’ 
intentions and behaviors. This occurs when patients’ feel that their healthcare providers lack 
technical or interpersonal competency, will not act in their best interests, or will not keep their 
information confidential.  
Antiretroviral therapy attitudes and beliefs are those feelings and opinions HIV+ patients have 
about taking their medication or about the therapy itself. The specific components of the 
construct were identified through exploratory factor analysis (see Chapter 4): psychological burden of 
medications, concerns about the physical and emotional effects of being on antiretroviral therapy 
as barriers to adherence; difficulty accessing medications, how hard it is for patients to obtain their 
prescribed medication; difficulty scheduling medications, changes in routine as barriers to adherence; 
and medication efficacy beliefs, how effective and important patients feel antiretroviral therapy to be.  
The degree of antiretroviral therapy adherence is the extent to which HIV+ patients take their 
medication as prescribed (Chesney et al., 2000). It is considered on a continuum from no or 
poor adherence to better or perfect adherence.  
 
  27 
Figure 3.1. Conceptual Model 
 
3.1.2 Description 
The conceptual model (Figure 3.1) hypothesizes that discriminatory healthcare experiences, 
healthcare provider distrust, and antiretroviral therapy attitudes and beliefs mediate the 
relationship between racial/ethnic minority status and antiretroviral therapy adherence. It is 
adapted from existing models of antiretroviral therapy adherence (Golin et al., 2002; Ickovics & 
Meade, 2002) described in the literature review. In the present study, the patient factors of 
interest were racial/ethnic minority status, discriminatory healthcare experiences (exposure from 
past healthcare providers), and antiretroviral therapy attitudes and beliefs. The provider factor of 
interest was healthcare provider distrust. The authors of existing models of antiretroviral therapy 
adherence posited direct effects of patient and provider factors on antiretroviral therapy 
adherence as well as bidirectional effects between patient and provider factors (Golin et al., 
2002; Ickovics & Meade, 2002). That is, patient factors may affect provider factors and vice 
versa. These feedback loops are important, but the present study teased apart those bidirectional 
effects to consider specific pathways by which patient factors indirectly influence adherence via 
provider factors and provider factors indirectly influence adherence via patient factors. Control 
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variables were selected from existing models for their association with antiretroviral therapy 
adherence: age, gender, year first diagnosed as HIV+, education, annual income, insurance 
status, AIDS diagnosis, viral load, CD4 count, self-reported physical and mental health, 
depression, dysthymia, type of illicit drug used, number of medications in regimen, social 
support, and adherence self-efficacy. Other potential covariates may be associated with 
discriminatory healthcare experiences or healthcare provider distrust (sexual orientation, HIV 
risk exposure, having a usual provider).  
These factors, however, are not expected to completely explain the relationship between 
racial/ethnic minority status and antiretroviral therapy adherence by HIV+ patients. The 
fundamental cause theory (Link & Phelan, 1995) posits that the health effects of social and 
economic inequality cannot be eliminated by addressing the mechanisms that appear to link 
them to disease. Fundamental causes, which influence multiple risk factors and multiple disease 
outcomes, have an enduring effect on health outcomes because the effect of one mechanism 
emerges or becomes more prominent as another declines (Link & Phelan, 1995). Therefore, I 
hypothesized that racial/ethnic minority status (as a crude proxy for experiences and 
expectations of racism in healthcare) will affect antiretroviral therapy adherence indirectly 
through more reports of discriminatory healthcare experiences (regardless of whether or not the 
unfair treatment is attributed to racial/ethnic minority status), increased healthcare provider 
distrust, and more negative antiretroviral therapy attitudes and beliefs. However, the relationship 
between racial/ethnic minority status and adherence will not be completely mediated by these 
proposed factors.   
Of secondary interest in this study are relationships among the hypothesized mediators. 
More discriminatory healthcare experiences may lead to greater healthcare provider distrust, and 
thus to poorer adherence. The hypothesized relationships with antiretroviral therapy attitudes 
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and beliefs are largely exploratory. Previous research suggests that racial/ethnic minority HIV+ 
patients may report different psychosocial barriers toward or hold more negative attitudes about 
antiretroviral therapy adherence than white patients (Ferguson et al., 2002). Thus I hypothesized 
that racial/ethnic minority HIV+ patients would have greater difficulty accessing antiretroviral 
medication and more negative beliefs about the efficacy of the treatment. In addition, 
antiretroviral therapy attitudes and beliefs may mediate the relationship between discriminatory 
healthcare experiences, healthcare provider distrust, and adherence. These potential pathways are 
not included in the following list of research questions and hypotheses, however. 
 
3.2. RESEARCH QUESTIONS AND HYPOTHESES 
Aim 1: To describe and examine the factors associated with discriminatory healthcare 
experiences and healthcare provider distrust among racial/ethnic minority and 
nonminority HIV+ patients.  
 
1.1 What is the prevalence of discriminatory healthcare experiences among HIV+ patients? 
 
1.2 Does the prevalence of discriminatory healthcare experiences among HIV+ patients vary 
by racial/ethnic minority status? 
(H 1.2) Minority HIV+ patients will report more discriminatory healthcare experiences than 
nonminority HIV+ patients. 
 
1.3 What factors are associated with discriminatory healthcare experiences by HIV+ 
patients? 
 
1.4 Do the factors associated with discriminatory healthcare experiences by HIV+ patients 
vary by racial/ethnic minority status? 
 
1.5 What is the prevalence of healthcare provider distrust among HIV+ patients? 
 
1.6 Does the prevalence of healthcare provider distrust among HIV+ patients vary by 
racial/ethnic minority status? 
(H 1.4) More minority HIV+ patients will distrust their healthcare providers than nonminority 
HIV+ patients. 
 
1.7 What factors are associated with healthcare provider distrust by HIV+ patients? 
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1.8 Do the factors associated with healthcare provider distrust by HIV+ patients vary by 
racial/ethnic minority status? 
 
Aim 2: To test a causal model of the relationships among racial/ethnic minority status, 
discriminatory healthcare experiences, healthcare provider distrust, antiretroviral 
therapy attitudes and beliefs, and antiretroviral therapy adherence.  
 
2.1 Is racial/ethnic minority status associated with antiretroviral therapy adherence? 
 (H 2.1.1.) Racial/ethnic minority HIV+ patients will have poorer adherence to antiretroviral therapy 
than nonminority HIV+ patients. 
 
2.2 Do discriminatory healthcare experiences partially mediate the relationship between 
racial/ethnic minority status and antiretroviral therapy adherence? 
  (H 2.2.1) As discriminatory healthcare experiences increases, adherence to antiretroviral therapy 
decreases. 
 (H 2.2.2) Minority HIV+ patients will have more discriminatory healthcare experiences and, in turn, 
poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
 
2.3 Does healthcare provider distrust partially mediate the relationship between racial/ethnic 
minority status and antiretroviral therapy adherence? 
(H 2.3.1) As healthcare provider distrust increases, adherence to antiretroviral therapy  
decreases. 
  (H 2.3.2) Minority HIV+ patients will have greater distrust in their healthcare providers and, in turn, 
poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
 
2.4 Do antiretroviral therapy attitudes and beliefs partially mediate the relationship between 
racial/ethnic minority status and antiretroviral therapy adherence? 
 (H 2.4.1) As (a) psychological burden of medication,(b) difficulty accessing medication,(c) difficulty 
scheduling medication, and (d) negative beliefs about medication efficacy increase, antiretroviral therapy 
adherence decreases. 
(H 2.4.2) Minority HIV+ patients will have greater difficulty accessing medication and, in turn, poorer 
adherence to antiretroviral therapy than nonminority HIV+ patients. 
(H 2.4.3) Minority HIV+ patients will have more negative beliefs in medication efficacy and, in turn, 
poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
 
 
 
  
 
 
CHAPTER FOUR:  
METHODS 
 
The present study is a secondary analysis of completed survey data from a national cohort of 
HIV+ patients. This chapter presents the: (1) research design of the original data source; (2) 
eligibility criteria for the secondary analysis; (3) construction and operationalization of study 
variables; and (4) analytical strategies by study aim.  
 
4.1. DATA SOURCE 
The HIV Cost and Services Utilization Study (HCSUS) was the first study to collect information 
on a national sample of HIV+ individuals in care (Frankel et al., 1999; Shapiro et al., 1999). The 
eligibility criteria for HCSUS were residence in the 48 contiguous states, aged 18 and over, 
known HIV infection, and receipt of medical care in facilities other than emergency 
departments, the military, or prisons. HCSUS used a panel design, with a baseline in-person 
interview conducted in January-February 1996 and follow-up interviews conducted 6 and 12 
months afterwards. The interviews assessed service access and utilization, cost and quality of 
care, quality of life, unmet service needs, social support, satisfaction with medical care, and 
knowledge of HIV therapies.  
4.1.1. Sampling Strategy  
HCSUS used multistage population-proportion-to-size (PPS) sampling for urban areas and 
purposive sampling for rural areas (Frankel et al., 1999; Shapiro et al., 1999). The PPS sampling 
  32 
was completed in three stages: (1) urban areas were randomly sampled proportional to numbers 
of AIDS cases reported; (2) providers within these areas were sampled proportional to their 
caseload using estimates obtained through provider surveys; and (3) HIV+ patients were 
sampled within practices, taking into account the possibility that individuals might obtain care 
from more than one site. Providers in rural areas were identified by a colleague-recruitment 
strategy. This complex sampling design required the use of analytic weights to correct for the 
inflated variance caused by clustering (Duan et al., 1999; Frankel et al., 1999; Shapiro et al., 
1999). Unless otherwise noted, all analyses were conducted with weighted data. 
4.1.2. Data Collection and Instrumentation 
Researchers surveyed 4042 HIV+ persons receiving care in 28 urban areas and 24 clusters of 
rural counties in the contiguous United States (Duan et al., 1999; Frankel et al., 1999; Shapiro et 
al., 1999). Of those surveyed, field interviewers completed full in-person structured interviews at 
baseline with 2864 (68%) individuals. Information on individuals too ill to complete the long-
form interview was collected from short-form in-person interviews or interviews with the 
participants’ medical provider. Similar methods were used for the first (6 month) and second (12 
month) follow-up interviews. All structured interviews were conducted using computer-assisted 
personal interview instruments.  
4.1.3. Study Sample 
Figure 4.1 presents the sampling strategy for the present study, which considered 
participants as “lost” if they did not complete the full interview or were otherwise lost to follow 
up (e.g., refusal).  For Aim 1, eligible participants are those who completed the long-form 
HCSUS survey at all three waves (n = 2267, 79% of those completing the full interview at 
baseline). For Aim 2, participants were excluded if they were not prescribed antiretroviral 
therapy by the second follow up interview (n = 356). The final sample of 1911 for Aim 2 
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represents 67% of baseline and 84% of the second follow-up. The present study was deemed 
exempt from full review by the Institutional Review Board of the University of North Carolina 
School of Public Health. 
 
Figure 4.1. Sample Selection 
Baseline (n = 2864) 
Follow Up 1 (n = 2466) 
AIM 1: Follow Up 2 (n = 2267) 
AIM 2: Prescribed Antiretroviral Therapy (n = 1911) 
Not Prescribed  
Antiretroviral Therapy (n = 356) 
Died (n = 73) 
Lost (n = 126) 
Died (n = 154) 
Lost (n = 244) 
Note: For the purposes of this study, participants who are “lost” are those who did not complete the full in-
person interview, refused to participate, or were unable to be contacted. 
 
Sources: Duan et al., 2001; Frankel et al., 1999; Shapiro et al., 1999 
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4.2. DATA PREPARATION 
The following section describes the data preparation activities for the current study. 
4.2.1. Missing Values 
The public use version of the HCSUS dataset imputed missing data on some variables with 
the hot-deck method (Duan et al., 1999). This method uses a matching process to identify 
observations to provide values for records with missing values. Variables used in the present 
study with 5% or more missing values are noted in Section 4.3, Measures. Section 4.4.2, Analyses 
for Aim 2, describes how missing values were handled during model testing.  
4.2.2. Measurement Construction and Assessment 
I used two methods, exploratory and confirmatory factor analysis, to develop all key study 
constructs. 
Exploratory factor analysis. Exploratory factor analysis (EFA) determined which items, selected 
based on face validity, defined the latent variables (unobserved variables or factors) that 
represent the study constructs (DeVellis, 2003). I conducted EFA to determine whether items 
held together without a priori constraints, which was important as many of the measures were 
newly developed for the present study. First, I identified factors using principal axis factor 
analysis with varimax rotation to seek items that substantially loaded on only one factor. To 
increase interpretability, I retained individual items that had loadings over 0.5 and did not have 
crossloadings on other factors of greater than 0.3 (DeVellis, 2003). I then retained factors with 
eigenvalues greater than 1.0 (Nunnally, 1978). Next, I examined item means and variances for 
variability and assessed reliability using inter-item correlations and item-total correlations. 
Finally, I computed the internal consistency of each factor using Cronbach’s alpha, which was 
deemed acceptable if above .70 (DeVellis, 2003). The final measures are described in Section 4.3, 
Measures; details of the exploratory factor analyses are presented in Appendix A. 
  35 
Confirmatory factor analysis. Confirmatory factor analysis (CFA) confirms or disconfirms 
hypotheses about the relationships between a set of indicators and their respective factors 
(DeVellis, 2003; Netemeyer, Bearden, & Sharma, 2003). CFA produces the measurement model 
used for structural equation modeling (SEM) for Aim 2 and is described in Section 4.4.2, 
Analyses.  
4.2.3. Screening 
I first examined the univariate descriptive statistics (e.g., distributions, means, measures of 
dispersion, residuals) for evidence of non-normal distributions. I then created bivariate scatter 
plots to determine linearity and checked for outliers; no influential cases were found. All key 
study variables exhibited floor and ceiling effects, being skewed and kurtotic.  
4.2.4. Attrition Analysis and Selection Bias 
I conducted t-tests, chi-square, Mann-Whitney U-tests (depending on variable type and 
normality of distribution), and multivariate regression to assess whether the individuals who died 
or were lost to follow up (n = 597) differed from those who remained in the study (n = 2267). 
In multivariate analyses, participants who completed all three waves of data collection (n = 2267) 
were less likely to be a member of a racial/ethnic minority group, have an AIDS diagnosis, and 
use heroin or cocaine in the past year than those who did not complete all waves (n = 597). 
Participants who completed all waves were more likely to be exposed to HIV through male-to-
female sexual contact and to have higher social support than those who did not complete all 
waves. Details of the attrition analysis are found in Appendix B.  
I also used these tests to see if participants who were prescribed antiretroviral medication at 
the second follow-up (n = 1911) differed on both the explanatory and control variables from 
those who were not prescribed antiretroviral therapy (n = 356). In multivariate analyses, 
participants who were on antiretroviral therapy (n = 1911) had higher viral loads and less distrust 
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of their healthcare provider than those who were not on antiretroviral therapy (n = 356). 
Participants who were on antiretroviral therapy were also more likely to have a higher income 
and an AIDS diagnosis than those who were not on antiretroviral therapy. Details of the 
selection bias analysis are found in Appendix B.  
 
4.3 MEASURES 
Table 4.1 describes the indicators, response format, and alpha of key study variables. All 
measures demonstrated acceptable to good internal consistency. Six of the seven measures used 
data collected at the second follow-up, making the research design for the present study 
primarily cross-sectional. Further description of the study measures are provided below. 
4.3.1. Dependent Variable 
Antiretroviral Therapy Adherence included five indicators obtained at the second follow up. For 
each medication participants reported taking, they were asked the number of days in the last 
seven that they forgot to take a dose, deliberately skipped a dose, took less medication than 
prescribed, and took all medication as prescribed. The value of each indicator was the mean days 
across medications, with the first three (FORGOT, SKIP, LESS) reverse coded. The fifth global 
indicator assessed the extent to which participants believed they took their antiretroviral 
medications exactly as prescribed in the last 30 days (1 = none of the time to 6 = all of the time). 
The items were summed and averaged to create a composite score. Higher scores meant better 
adherence.  
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Table 4.1. Key Study Measures  
 
Construct Wave* Item Response Format Alpha 
 
• #Days in last 7 forgot 
to take a dose (reverse) 
• #Days in last 7 
purposely skipped dose 
(reverse) 
• #Days in last 7 took 
lesser amount (reverse) 
• #Days in last 7 took as 
prescribed  
 
0 - 7  
 
Antiretroviral Therapy 
Adherence 
 
B 
• Took meds exactly as 
prescribed in the last 
30 days 
1 = none of the time, 
6 = all of the time 
 
.82 
 
B 
 
• Exhibited hostility or a 
lack of respect to 
participant 
B • Gave less attention to 
participant than to 
other patients 
B • Refused service to 
participant 
FU 1 • Was uncomfortable 
with participant 
FU 1 • Treated participant as 
inferior  
 
Discriminatory 
Healthcare Experiences  
FU 1 • Preferred to avoid 
participant 
 
0 = no,  
1 = yes 
 
 
 
.84 
 
• Trust to offer quality 
care 
• Trust to know best 
treatments 
• Trust to give enough 
information 
• Trust to keep personal 
information private 
• Trust to treat patient 
nonjudgmentally 
• Trust to offer high 
quality care regardless 
of insurance coverage 
 
Healthcare Provider 
Distrust 
 
FU 2 
• Trust to put patient 
needs ahead of 
 
1= completely,  
5 = not at all 
 
.92 
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Construct Wave* Item Response Format Alpha 
research goals 
 
• Too many pills to take 
• Wanted to avoid side 
effects 
• Reminded self of HIV 
status 
• Health wasn’t 
improving 
• Worried about 
becoming immune 
• Took a “drug holiday” 
 
Psychological Burden of 
Medication 
 
FU 2 
• Felt depressed or 
overwhelmed 
 
1 = often, 4 = never 
 
.85 
 
• Hard to get HIV 
medications 
• Easy to get HIV 
prescriptions (reverse) 
• Takes a lot of time and 
effort to get HIV 
medication 
 
Difficulty Accessing 
Medication 
 
FU 2 
• HIV medication would 
be hard to get if it runs 
out 
 
1 = strongly agree,  
4 = strongly disagree 
 
.71 
 
• Away from home  
• Too busy or forgot 
 
Difficulty Scheduling 
Medication 
 
FU 2 
• Change in daily routine 
 
 
1 = often, 4 = never 
 
.76 
 
• HIV medications make 
people live longer 
 
Medication Efficacy 
Beliefs 
 
FU 2 
• HIV medications 
improve the quality of 
people’s lives 
 
1 = strongly agree,  
4 = strongly disagree 
 
.72 
*B = baseline; FU 1 = 1st follow up; FU 2 = 2nd follow up 
 
4.3.2. Independent Variables 
Discriminatory Healthcare Experiences had three dichotomous indicators obtained at baseline and 
three at the first follow up interview. Participants reported at baseline whether, since they had 
become HIV+, any healthcare provider had ever exhibited hostility or disrespect to them, paid 
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less attention to them than other patients, or refused them service. At the first follow-up 
interview, participants reported whether any healthcare provider had ever been uncomfortable 
around them, treated them as inferior, or preferred to avoid them since becoming HIV+. Even 
though the data were collected in two waves, the items were considered as a group as 
retrospective indicators of separate experiences. The items were summed and averaged to create 
a composite score. Higher scores meant more experiences with discrimination in healthcare 
settings.  
Healthcare Provider Distrust had seven indicators obtained at the second follow up interview 
assessing the extent to which participants trusted their current primary provider of HIV/AIDS 
care. On a 5-point scale (1 = completely to 5 = not at all), participants reported the degree that 
they trusted their healthcare provider to offer quality care, know the best treatments, provide 
enough information, keep personal information confidential, treat them in a nonjudgmental 
manner, offer high quality care regardless of insurance status, and put participant needs ahead of 
research goals. The items were summed and averaged to create a composite score. Higher scores 
meant greater distrust in healthcare providers.  
Four factors captured participants’ attitudes and beliefs about antiretroviral therapy, with all 
indicators obtained at the second follow up interview: 
• Psychological Burden of Medication had eight indicators of the degree to which participants 
had worries and concerns about taking antiretroviral therapy (e.g., too many pills to 
take, reminded self of HIV status, concern about developing immunity), with higher 
scores meaning greater psychological burden. Each indicator was measured on a 4-point 
scale (1 = never to 4 = often).  
• Difficulty Accessing Medication had four indicators assessing the degree to which participants 
felt that obtaining antiretroviral therapy was difficult (e.g., hard to get HIV medications, 
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takes a lot of time and effort to get HIV medications), with higher scores meaning 
greater difficulty. Each indicator was measured on a 4-point scale (1 = strongly disagree 
to 4 = strongly agree).  
• Difficulty Scheduling Medication had three indicators assessing the extent to which changes 
in participants’ routines impeded their adherence to antiretroviral therapy (e.g., being 
away from home, too busy or forgot), with higher scores meaning greater difficulty. 
Each indicator was measured on a 4-point scale (1 = never to 4 = often).  
• Medication Efficacy Beliefs had two indicators assessing the extent to which participants 
believed antiretroviral therapy promoted longer and better quality lives, with higher 
scores meaning more positive beliefs about the efficacy of antiretroviral therapy. Each 
indicator was measured on a 4-point scale (1 = strongly disagree to 4 = strongly agree).  
The items for each construct were summed and averaged to create a composite score. 
Racial/Ethnic Minority Status was dummy coded as 0 if participants self-classified as White 
race, non-Hispanic ethnicity and 1 otherwise. I did not use alternate coding schemes to test for 
differences among racial/ethnic groups because of inadequate sample sizes of the Hispanic (n = 
272) and “other” group (n = 65) samples among participants who completed all waves of data 
collection and were prescribed antiretroviral therapy (n = 1911).  
4.3.3. Control Variables 
The control variables used in these analyses, chosen for their potential for confounding the 
relationships between racial/ethnic minority status and adherence, were selected from derived 
variables created by the HCSUS research team (Duan et al., 2001):  
• The original responses for Age at baseline were 1 for 18-29 years, 2 for 30-34, 3 for 35-
39, 4 for 40-44, 5 for 45-49, and 6 for 50 years and over. This variable was recoded to 
its category’s midpoint to approximate a continuous scale. 
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• Gender, assigned by the interviewer at baseline, was an indicator with 0 for male and 1 for 
female.  
• Sexual Orientation was a nominal variable obtained at baseline, coded as 1 for homosexual, 
2 for heterosexual, and 3 for bisexual. Two dummy variables for heterosexual and 
bisexual orientation, with homosexual as the reference category, were used in 
multivariate analyses.  
• HIV Risk Exposure described the manner in which the participant became infected with 
HIV. Obtained at baseline, this nominal variable was coded as 1 for injection drug use, 
2 for male-to-male sexual contact, 3 for male-to-female sexual contact, and 4 for other 
(e.g., blood transfusion). When more than one possible transmission was selected (e.g., 
men having sex with men/injection drug use), the first method listed was selected. 
Three dummy variables were used for multivariate analyses with male-to-male sexual 
contact as the reference category.  
• The Year First Diagnosed as HIV+ was a continuous variable ranging from 1978 to 1996, 
with 11.8% (n = 337) missing values. The earlier the year, the longer participants had 
known their HIV status.  
• Education at baseline was the highest degree obtained by the participant, with responses 
ranging from 1 for less than a high school degree to 4 for a bachelor’s degree or higher. 
Three dummy variables were used for multivariate analyses, with less than high school 
as the reference category. 
• The original responses for Annual Income, participant’s individual earnings in 1995, ranged 
from 1 for $0 – $5000 to 5 for $40000 or more. This variable was recoded to its 
category’s midpoint to approximate a continuous scale. 
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• At baseline, primary Insurance Status in the past six months was derived using hierarchical 
assignment. First, participants with Medicare were assigned to the Medicare category 
regardless of other insurance. Next, if the Medicare data were not missing and 
participants had private insurance or CHAMPUS (private managed care for military), 
they were assigned to the private insurance category. Then, if participants had Medicaid 
or Veterans Administration coverage (publicly financed health benefits for military) and 
no missing data on Medicare, private insurance, or CHAMPUS, then they were assigned 
to the Medicaid category. Otherwise, participants were categorized as having no 
insurance. Multivariate analyses used three dummy variables for Medicare, private, and 
Medicaid insurance, with no insurance as the reference category.  
• AIDS Diagnosis was an indicator variable with 0 for no and 1 for yes if, at baseline, 
participants had either a CD4 count of less than 200 or a clinical diagnosis of AIDS.  
• The most recent Viral Load at second follow up was categorized as 1 for undetectable to 
7 for 100,000 or more copies/ml. This variable was recoded to its category’s midpoint 
to approximate a continuous scale. The lower the viral load, the healthier the participant 
was considered to be. There were 15.6% (n = 354) missing values.  
• The lowest ever reported CD4 Count at baseline was categorized as 1 for 0 – 49 and 4 for 
500 or more. This variable was recoded to its category’s midpoint to approximate a 
continuous scale. The higher the CD4 count, the healthier the participant was 
considered to be. There were 16.6% (n = 376) missing values. 
• The Physical Health Composite and Mental Health Composite scores were standardized 
measures of Health-Related Quality of Life subscales of the Medical Outcomes Study 
Short Form Health Survey (SF-36) (Hays et al., 2000) obtained at baseline. Higher 
scores indicated better physical and mental health.  
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• Depression is a disabling episode that is characterized by such symptoms as persistent 
sadness, feelings of hopelessness and pessimism, and decreased energy (NIMH, 2000). 
The number of Depression Symptoms, measured at baseline, was a count variable with the 
range 0 – 8.  
• Dysthymia is a less severe form of depression but one that was long-term and chronic 
(NIMH, 2000). The number of Dysthymia Symptoms, measured at baseline, is a count 
variable with the range 0 – 4. 
• At baseline, Type of Drug Used in Past Year was derived using hierarchical assignment 
(Tucker et al., 2003). Participants who did not use any illicit drug in the past year were 
assigned to the no use category. Participants who reported any illicit drug use were 
assigned to one of three additional categories. The first category was those who 
reported using marijuana and analgesics, but no other illicit drugs. The second category 
was those who reported any use of inhalants, hallucinogens, sedatives, and 
amphetamines, but not heroin or cocaine. The third category was those who reported 
any use of heroin and cocaine. Three dummy variables were used for multivariate 
analyses, with no use as the reference category.  
• At the second follow up, participants reported the Number of Antiretroviral Medications that 
they were prescribed.  
• Usual Provider at baseline was an indicator variable (0 = no, 1 = yes) for whether 
participants usually saw the same healthcare provider for their HIV/AIDS care. 
• Social Support was defined as functions performed by others that are intended to be 
helpful (Fleishman et al., 2000). This was a standardized composite variable (range 0 – 
100) measuring at baseline the degree to which participants felt they had someone who 
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could give them money, help with daily chores, and love them. The higher the score, the 
more perceived social support the participant had. 
• Adherence Self-Efficacy was an ordinal variable assessing the extent to which participants 
believed they would be able to take their antiretroviral therapy exactly as prescribed over 
the next month (1 = strongly agree to 4 = strongly disagree).  
 
4.4. DATA ANALYSIS 
I performed the analysis in three stages. First, I conducted descriptive and bivariate analyses. 
Second, I used multiple regression to determine the independent associations between the 
dependent and six explanatory variables. These first two stages were performed using 
Intercooled STATA, version 8.2 (STATA Corporation, 2003), which incorporates the analytic 
weights required by the complex sampling design used in the HCSUS dataset. Third, I used 
structural equation modeling (SEM) to identify the direct and indirect effects of the study 
measures on antiretroviral therapy adherence. The SEM analyses were performed using MPlus, 
version 3.11 (Muthen & Muthen, 2004), which can handle categorical data, non-normally 
distributed data, and analytic weights. Below, I describe these strategies in more detail. 
4.4.1. Analyses for Aim 1 
Descriptive statistics. The first aim was to describe and examine discriminatory healthcare 
experiences, healthcare provider distrust, and their determinants among HIV+ patients. The 
sample for Aim 1 included all participants who had completed all three waves of data collection 
(n = 2267). I generated descriptive statistics (e.g., proportions or means, standard deviations, 
confidence intervals) for each variable, stratified by racial/ethnic minority status. For the key 
study measures, I used mean composite scores based on construct indicators instead of factor 
scores to increase data interpretability; the correlation between the two types of variables was 
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greater than .99 for all measures. Simple linear regression was conducted to determine the 
unadjusted bivariate associations among the control variables, discriminatory healthcare 
experiences, and healthcare provider distrust. The significance level for all analyses was set at 
probability value of less than or equal to .05 but variables with a probability value of .20 or less 
in bivariate analyses were included in the multivariate models. This liberal cut off point was used 
because of the exploratory nature of the analysis. 
Regression analyses. I used multivariate linear regression to identify independent associations 
between discriminatory healthcare experiences, healthcare provider distrust, and the control 
variables. To assess whether the factors associated with discriminatory healthcare experiences 
and healthcare provider distrust varied by minority status, interaction terms were added to each 
regression equation. Interaction terms with a probability value greater than .05 were then 
dropped from the full model so that the main effects could be interpreted.  
4.4.2. Analyses for Aim 2 
Descriptive statistics. The second aim was to test causal models of the relationships among 
racial/ethnic minority status, discriminatory healthcare experiences, healthcare provider distrust, 
antiretroviral therapy attitudes and beliefs, and antiretroviral therapy adherence. The sample for 
Aim 2 included all participants who had completed three waves of data collection and who were 
taking antiretroviral medications at the time of the second follow up interview (n = 1911). I 
generated descriptive statistics for each variable, stratified by racial/ethnic minority status. Next, 
I conducted simple linear regression to determine the unadjusted bivariate associations between 
the explanatory variables, control variables, and antiretroviral therapy adherence. The 
significance level for all analyses was set at probability value less than or equal to .05 but 
variables with a probability value of .20 or less in bivariate analyses were included in the 
structural equation models.  
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Model testing. I tested hypotheses regarding mediators of the relationship between 
racial/ethnic minority status and antiretroviral therapy adherence using structural equation 
modeling. SEM proposes a set of relations between variables and evaluates the degree of model 
fit with observed data (Bollen, 1989; Hoyle & Smith, 1994; Kline, 1998; MacCallum & Austin, 
2000). SEM is considered an efficient means of testing mediation because it: (1) controls for 
measurement error; (2) allows for computation of direct effects through inclusion of third 
variables; and (3) allows estimation of models with multiple mediators or mediation/moderation 
combinations (Hoyle & Smith, 1994). This technique does not allow researchers to identify a 
“true” model. Rather, multiple models may fit the data and researchers must use their own 
judgment to determine whether a given model corresponds with reality (Bollen, 1989; Hoyle & 
Smith, 1994; Kline, 1998; MacCallum & Austin, 2000). 
The general structural equation model consists of the measurement model and structural 
model (Bollen, 1989; Hoyle & Smith, 1994). The measurement model is a set of hypotheses 
about the relationship between observed and latent variables (i.e., the confirmatory factor 
analysis described earlier). Measurement error is represented as a latent variable in the 
measurement model because it is inferred, not directly assessed. To provide a unit scale for each 
latent variable, the factor loading of one indicator was constrained to 1.0 (Bollen, 1989; Kline, 
1998). The structural model is a set of hypotheses about the relationships between independent 
and dependent variables, whether observed or latent (Bollen, 1989; Hoyle & Smith, 1994). I 
produced model parameters using weighted least square mean- and variance-adjusted estimation 
(WLSMV), a robust method that accounts for the non-independent, non-normal observations 
and is used when at least one categorical variable is incorporated in the model (Muthen & 
Muthen, 2004).  
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I imputed missing data using the MISSING command in MPlus, which is a missing at 
random (MAR) maximum likelihood data method (Muthen & Muthen, 2004). This means that 
the missing data can be modeled as a function of observed covariates and observed outcomes. 
This strategy cannot be used for exogenous variables, however. The control variable Viral Load 
was thus dropped from the SEM analysis because the large amount of missing data (n = 354, 
15.6%) produced unstable estimates. The other control variables with large amounts of missing 
data, year first diagnosed as HIV+ and lowest ever CD4 count, were not significantly associated 
with antiretroviral therapy adherence in bivariate analyses and thus not included in multivariate 
analyses. 
I used a model-generating strategy to build a good-fitting model (Kline, 2005). This strategy 
allows the researcher to add or delete parameters to improve model fit based on both 
researcher’s content knowledge and modification indices (Lagrange multiplier and Wald 
statistics) calculated by the SEM program. In all cases, however, theoretical plausibility trumps 
modification indices when deciding what paths to add to an existing model. Nonsignificant 
paths were dropped in the final model. Following Hu and Bentler (1998), models were 
considered to have a good fit if: (1) the ratio of χ2 to degrees of freedom (CMINDF) was less 
than 3.04; (2) the root mean square error of approximation (RMSEA) was .06 or less; (3) and the 
Tucker-Lewis (TLI) and Comparative Fit (CFI) indices were .95 or greater (Hu & Bentler, 1998). 
Because the models included categorical indicators, I used the weighted root mean residual 
(Muthen & Muthen, 2004) instead of the recommended standardized root mean residual 
(SRMR). WRMR should have a score of 1.00 or less (Muthen, 2004). 
                                                 
4 The chi-square statistic is a basic model fit index, with nonsignificant results demonstrating good fit. However, the 
chi-square statistic is sensitive to large sample sizes (Bollen, 1989; Kline, 2005), which is the case for the present 
study. Therefore I reported the normed chi-square (ratio of chi square to degrees of freedom) instead. 
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I assessed statistical significance of unstandardized parameter estimates based on the 
absolute value of the critical ratio test statistic (estimate divided by its standard error; considered 
as a t score), whose absolute value should be greater than 1.96 for a probability value of .05 or 
less. I also checked whether the parameter estimate had the hypothesized sign and assessed the 
magnitude of the standardized estimates according to Cohen’s (1988) typology of small (.10 or 
less), medium (around .30), and large (.50 or more) effects. All models controlled for the effects 
of sociodemographic and psychosocial factors associated with antiretroviral therapy adherence.  
Finally, I conducted an effects decomposition using the MODEL INDIRECT command of 
MPlus (Muthen & Muthen, 2004). This produces the total, direct, and indirect effects of study 
constructs on the outcome (in this case, antiretroviral therapy adherence). The direct effect is the 
parameter estimate of the relationship between one construct and the outcome. Indirect effects 
are parameter estimates of mediating pathways. The total effect is the sum of the direct and 
indirect effects. The strongest evidence for mediation comes when there is a pattern of 
significant indirect effects but nonsignificant direct effects (Kline, 2005). 
 
 
 
 
 
 
 
 
CHAPTER FIVE:  
RESULTS 
 
This chapter reports study findings by research aim. Each aim includes sample characteristics 
and bivariate analyses. Aim 1 includes multivariate regression models and Aim 2 includes 
structural equation models. The chapter concludes with a summary of the support for the study 
hypotheses.  
 
5.1. AIM 1 
To describe and examine the factors associated with discriminatory healthcare experiences and 
healthcare provider distrust, two consequences of stigma in interpersonal care quality, 
among racial/ethnic minority and nonminority HIV+ patients. 
 
5.1.1. Sample Description 
Table 5.1 presents descriptive statistics for the sample for Aim 1 (n = 2267) stratified by 
racial/ethnic minority status. Of the minority sample (n = 1109), 64% were African American 
(non-Hispanic), 29% were Hispanic/Latino, and 7% reported another racial/ethnic category. 
The minority sample differed from the nonminority sample on most sociodemographic 
characteristics. Compared to nonminorities, minority participants were more likely to be female, 
younger, have less than a high school degree, earn less than $25,000 annually, to have been on 
Medicaid, identify as heterosexual, report exposure to HIV through injection drug use or male-
to-female sexual contact. Minority participants also were more likely to have a more recent HIV 
diagnosis, and to have used heroin or cocaine in the past year. Minorities were less likely than 
nonminorities to identify as homosexual, have private insurance, or to have an AIDS diagnosis. 
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Minority participants reported fewer symptoms of depression, more symptoms of dysthymia, 
and less social support than did nonminority participants. 
 
Table 5.1. Sample Characteristics for Aim 1 by Minority Status 
 
 Minority 
(n = 1109),  
% or Mean (SD) 
Nonminority 
(n = 1158),  
% or Mean (SD) 
 
 
p 
 
Female 
 
34.1 
 
12.4 
 
<.001 
 
< 35 Years Old 
 
35.8 
 
3.3 
 
.016 
 
< High School Degree 
 
36.5 
 
12.5 
 
<.001 
 
 
< $25,000 Annual Income 
 
 
84.4 
 
 
56.4 
 
 
<.001 
 
Insurance in Last 6 Months 
     None 
     Medicaid 
     Medicare 
     Private 
 
 
19.9 
16.7 
2.9 
2.8 
 
 
15.6 
4.8 
18.5 
46.8 
 
 
<.001 
 
 
Sexual Orientation 
     Homosexual 
     Heterosexual 
     Bisexual 
 
 
28.8 
62.4 
8.9 
 
 
68.0 
24.8 
7.1 
 
 
<.001 
 
Risk Exposure 
     Injection Drug Use 
     Male-to-Male Sexual Contact 
     Male-to-Female Sexual Contact 
     Other 
 
 
27.0 
32.4 
29.8 
1.8 
 
 
2.3 
65.6 
8.6 
5.5 
 
 
<.001 
 
Year Diagnosed HIV+ 
 
1992 (3.1) 
 
1990 (3.4) 
 
<.001 
 
Has AIDS Diagnosis 
 
54.3 
 
62.1 
 
.009 
 
Viral Load 1000 copies/ml or less  
 
15.5 
 
24.7 
 
<.001 
 
Lowest Ever CD4 Count < 200  
 
11.3 
 
16.6 
 
<.001 
 
Self-Perceived Physical Health 
 
49.8 (1.2) 
 
49.6 (1.1) 
 
.600 
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 Minority 
(n = 1109),  
% or Mean (SD) 
Nonminority 
(n = 1158),  
% or Mean (SD) 
 
 
p 
 
Self-Perceived Mental Health  
 
49.7 (1.1) 
 
49.9 (1.3) 
 
.709 
 
Depression Symptoms 
 
1.6 (2.9) 
 
2.0 (3.1) 
 
.003 
 
Dysthymia Symptoms 
 
1.1 (1.6) 
 
.8 (1.5) 
 
<.001 
 
Used Heroin or Cocaine in Past Year 
 
18.6 
 
12.6 
 
<.001 
 
Has Usual HIV Provider 
 
91.2 
 
92.0 
 
.677 
 
Social Support 
 
62.6 (28.0) 
 
68.1 (28.7) 
 
<.001 
 
5.1.2. Prevalence 
1.1 What is the prevalence of discriminatory healthcare experiences among 
HIV+ patients? 
 
1.2 Does the prevalence of discriminatory healthcare experiences among 
HIV+ patients vary by racial/ethnic minority status? 
(H 1.2) Minority HIV+ patients will have more discriminatory healthcare experiences than 
nonminority HIV+ patients.  
 
More than one-third of participants (41%) reported ever experiencing at least one type of 
discrimination in healthcare settings since they were diagnosed with HIV. Table 5.2 shows the 
proportion of minority and nonminority participants who reported ever having each type of 
discriminatory healthcare experience. The most common experience reported across groups was 
that healthcare providers exhibited hostility or lack of respect towards the participant (27%), 
followed by providers giving less attention to participants than to other patients (21%) and 
providers being uncomfortable with patients (20%). The mean number of experience types 
reported by minorities was lower than that reported by nonminorities (.8 [CI95: .7, .9] vs. 1.5 
[CI95: 1.4, 1.6], Mann-Whitney z [1878] = 7.17, p < .01) and the prevalence of all types of 
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discrimination was lower among minorities than nonminorities. Thus, Hypothesis 1.2 was not 
supported.  
 
Table 5.2. Prevalence of Discriminatory Healthcare Experiences by Minority Status 
 
 % Ever Experienced Discrimination 
 
Type of Experience 
Minority  
(95% CI) 
Nonminority 
(95% CI) 
 
p 
 
Exhibited hostility, lack of respect to patient 
 
19.8 (16.5, 23.5) 
 
33.5 (29.7, 37.5) 
 
<.001 
 
Gave less attention than to other patients 
 
14.7 (11.4, 18.9) 
 
25.8 (22.1, 3.1) 
 
<.001 
 
Been uncomfortable with patient 
 
12.3 (1.5, 14.5) 
 
27.1 (22.7, 31.9) 
 
<.001 
 
Treated patient as inferior 
 
11.8 (9.3, 15.0) 
 
22.7 (18.2, 27.9) 
 
.002 
 
Preferred to avoid patient 
 
11.7 (1.2, 13.3) 
 
24.7 (2.3, 29.8) 
 
<.001 
 
Refused service to patient 
 
1.1 (8.2, 12.5) 
 
5.9 (4.3, 8.0) 
 
.013 
Note. Because of missing data across items, the minority sample size ranges from 1106 to 1109 and the nonminority 
sample size ranges from 1147 to 1158. 
 
Participants most commonly attributed discriminatory healthcare experiences to their HIV 
status (79%), followed by their sexual orientation (31%) and race (13%)5. Minority participants 
were significantly less likely than nonminorities to attribute these experiences to their HIV status 
(74% vs. 83%, χ2 [1, 687] = 8.1, p = .010) or sexual orientation (19% vs. 40%, χ2 [1, 676] = 34.4, 
p < .001). Minority participants were more likely than nonminorities to attribute discriminatory 
healthcare experiences to their race (27% vs. 5%, χ2 [1, 696] = 7.1, p < .001). There were no 
differences in attributions to gender or drug use.  
                                                 
5 Descriptive statistics on attributions to discrimination were computed without weights because a stratum with only 
one population sampling unit was detected. 
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1.3 What is the prevalence of healthcare provider distrust among HIV+ 
patients? 
 
1.4 Does the prevalence of healthcare provider distrust among HIV+ patients 
vary by racial/ethnic minority status? 
(H 1.4) More minority HIV+ patients will distrust their healthcare provider than 
nonminority HIV+ patients.  
 
Across domains, low proportions of participants distrusted their healthcare providers (Table 
5.3). The proportion of those who did not completely or almost completely trust their healthcare 
provider did not vary by minority status except for the domain regarding research goals (10.7% 
Minority vs. 8.0% Nonminority, χ2 [1, 2267] = 23.94, p < .001).  Hypothesis 1.4 was thus largely 
unsupported. Using a more conservative definition that considered as distrustful only 
participants who did not completely trust their healthcare provider increased the proportion of 
the sample considered distrustful by approximately 10% across domains, but the difference by 
minority status for research goals was no longer significant (22.3% Minority vs. 23.4% 
Nonminority, χ2 [1, 2267] = 4.09, p = .231). Racial/ethnic minority and nonminority participants 
also did not differ in the degree of healthcare provider distrust in an unadjusted bivariate analysis 
(Mann-Whitney z [2263] = .05, p = .963).  
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Table 5.3. Prevalence of Healthcare Provider Distrust by Minority Status 
 
 % Who Do Not Trust  
Their Healthcare Provider  
Completely or Almost Completely 
 
Trust Domain 
Minority 
(95% CI) 
Nonminority 
(95% CI) 
 
p 
 
Put patient needs ahead of research goals 
 
10.7 (8.7, 13.0) 
 
8.0 (6.6, 9.7) 
 
<.001 
 
Offer high quality care regardless of insurance 
 
7.3 (5.6, 9.4) 
 
6.7 (5.0, 9.0) 
 
.13 
 
Give enough information 
 
5.5 (4.3, 7.1) 
 
6.3 (5.3, 7.5) 
 
.96 
 
Offer quality care 
 
5.1 (4.0, 6.5) 
 
4.3 (3.3, 5.6) 
 
.08 
 
Respond in a caring and nonjudgmental way 
 
5.1 (4.0, 6.6) 
 
5.7 (4.4, 7.3) 
 
.84 
 
Know best treatments 
 
4.6 (3.7, 5.6) 
 
3.9 (3.0, 5.0) 
 
.09 
 
Keep personal information private 
 
4.1 (3.0, 5.5) 
 
3.1 (2.3, 4.2) 
 
.07 
Note. Because of missing data, the minority sample size ranges from 1045 to 1107 and the nonminority sample 
ranges from 1119 to 1154 across items. 
 
 
5.1.3.  Sociodemographic and Psychosocial Factors 
 
1.5 What factors are associated with exposure to discriminatory healthcare 
experiences by HIV+ patients? 
1.6 Do the factors associated with discriminatory healthcare experiences by 
HIV+ patients vary by racial/ethnic minority status? 
 
Table 5.4 shows the unadjusted bivariate associations6 between discriminatory healthcare 
experiences and potential sociodemographic and psychosocial factors. Higher discrimination 
scores were associated with nonminority status, higher education level, having Medicare or no 
insurance, homosexual orientation, having HIV risk exposure through male-to-male sexual 
contact, longer HIV infection, having an AIDS diagnosis, poorer physical and mental health, 
                                                 
6 Unstandardized betas (β) are regression coefficients that represent the amount of change in the dependent variable 
given a 1-unit change in the independent variable. By definition, these coefficients cannot be compared across 
variables as they are not standardized. 
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more symptoms of depression and dysthymia, taking any illicit drug in the past year, and less 
social support.  
 
Table 5.4. Bivariate Associations between Discriminatory Healthcare Experiences  
and Potential Sociodemographic and Psychosocial Factors  
 
 Discriminatory  
Healthcare Experiences 
 β (95% CI) p 
 
Minority 
 
-.72 (-1.06, -.39) 
 
<.001 
 
Female 
 
-.14 (-.31, .01) 
 
.064 
 
Age 
 
-.03 (-.07, .01) 
 
.150 
 
Education 
     High School 
     Less than College 
     College or Higher 
     Less than High School 
 
 
.34 (.11, .57) 
.75 (.41, 1.09) 
.40 (.19, .62) 
(reference) 
 
 
.005 
<.001 
<.001 
 
Annual Income 
 
.03 (-.04, .10) 
 
.358 
 
Insurance Status  
    Medicaid 
    Medicare 
    Private 
    None 
 
 
.14 (-.18, .45) 
.65 (.47, .83) 
-.58 (-.79, -.37) 
(reference) 
 
 
.384 
<.001 
<.001 
 
 
Sexual Orientation 
    Heterosexual 
    Bisexual 
    Homosexual 
 
 
-.29 (-.43, -.15) 
-.19 (-.60, .24) 
(reference) 
 
 
<.001 
.386 
 
Risk Exposure 
    IDU 
    Male-to-Female Sexual Contact 
    Other 
    Male-to-Male Sexual Contact 
 
 
.06 (-.14, .27) 
-.32 (-.54, -.11) 
-.30 (-.58, -.02) 
(reference) 
 
 
.542 
.004 
.036 
 
 
Year Diagnosed HIV+ 
 
-.09 (-.12, -.06) 
 
<.001 
 
AIDS Diagnosis 
 
.37 (.21, .53) 
 
<.001 
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 Discriminatory  
Healthcare Experiences 
 β (95% CI) p 
 
Viral Load 
 
-.03 (-.06, .00) 
 
.086 
 
Lowest Ever CD4 Count 
 
-.07 (-.15, .01) 
 
.084 
 
Self-Reported Physical Health 
 
-.04 (-.05, -.04) 
 
<.001 
 
Self-Perceived Mental Health  
 
-.04 (-.05, -.03) 
 
<.001 
 
Depression Symptoms 
 
.12 (.09, .15) 
 
<.001 
 
Dysthymia Symptoms 
 
.15 (.10, .20) 
 
<.001 
 
Type of Drug Used in Past Year 
     Marijuana or Analgesics 
     Inhalants, Hallucinogens, Sedatives, or Amphetamines 
     Heroin or Cocaine 
     No Use 
 
 
.54 (.35, .75) 
.63 (.40, .86) 
.34 (.12, .57) 
(reference) 
 
 
<.001 
<.001 
.004 
 
Usual HIV Provider 
 
-.01 (-.34, .31) 
 
.941 
 
Social Support 
 
-.01 (-.01, .00) 
 
<.001 
Note. Because of missing data, the sample sizes across items range from 1864 to 2232. 
 
 
Multivariate associations between discriminatory healthcare experiences and baseline 
sociodemographic characteristics are shown in Table 5.5. To assess whether the factors 
associated with discriminatory healthcare experiences varied by minority status, interaction terms 
were added to the original regression equation. Interaction terms with a p-value greater than .05 
were then dropped from the full model so the main effects could be interpreted. In the reduced 
model (Table 5.5), significant interaction effects were found between minority status and 
depression symptoms. That is, minority HIV+ patients with fewer symptoms of depression had 
higher discrimination scores than minority HIV+ patients with more symptoms of depression. 
Significant interaction effects were also found between minority status and HIV risk exposure. 
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That is, minority HIV+ patients who were exposed to HIV through male-to-male sexual contact 
had higher discrimination scores than minority HIV+ patients who were exposed to HIV in 
other ways (e.g., injection drug use, male-to-female sexual contact). For both minority and 
nonminority patients, higher discrimination scores were associated with having less than a 
college degree, being diagnosed with HIV earlier, having an AIDS diagnosis, ever having a CD4 
count less than 200, poorer physical health, using any illicit drug in the past year except heroin or 
cocaine, and having less social support. The two interaction terms explained less than an 
additional 1% of the variance in discriminatory healthcare experiences. 
 
Table 5.5. Final Reduced Model of the Interaction between Minority Status and Factors 
Associated with Discriminatory Healthcare Experiences (n = 1840) 
 
 Discriminatory  
Healthcare Experiences 
 β  (95% CI) p 
 
Minority 
 
-.32 (-.58, -.05) 
 
.020 
 
Female 
 
-.02 (-.25, .21) 
 
.855 
 
Age 
 
-.05 (-.10, .01) 
 
.086 
 
High School 
 
.25 (-.01, .51) 
 
.063 
 
Less than College 
 
.60 (.27, .93) 
 
.001 
 
College 
 
.25 (-.05, .55) 
 
.100 
 
Medicare 
 
.15 (-.16, .47) 
 
.336 
 
Private Insurance 
 
-.27 (-.63, .09) 
 
.141 
 
Heterosexual Orientation 
 
.09 (-.08, .26) 
 
.305 
 
Male-to-Female Sexual Contact 
 
.08 (-.15, .30) 
 
.487 
 
Other Risk Exposure 
 
.60 (-.04, 1.24) 
 
.067 
 
Year Diagnosed HIV+ 
 
-.07 (-.10, -.04) 
 
<.001 
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 Discriminatory  
Healthcare Experiences 
 β  (95% CI) p 
 
AIDS Diagnosis 
 
.29 (.12, .46) 
 
.001 
 
Viral Load 
 
.00 (-.05, .04) 
 
.885 
 
Lowest Ever CD4 Count 
 
-.17 (-.28, -.06) 
 
.005 
 
Self-Reported Physical Health 
 
-.03 (-.04, -.02) 
 
<.001 
 
Self-Reported Mental Health 
 
.00 (-.02, .01) 
 
.533 
 
Depression Symptoms 
 
.08 (.04, .12) 
 
<.001 
 
Dysthymia Symptoms 
 
.05 (-.01, .10) 
 
.076 
 
Used Marijuana or Analgesics in Past Year 
 
.31 (.14, .47) 
 
<.001 
 
Used Inhalants, Hallucinogens, Sedatives, or 
Amphetamines in Past Year 
 
.21 (.04, .38) 
 
.016 
 
Used Heroin or Cocaine in Past Year 
 
.09 (-.15, .33) 
 
.441 
 
Social Support 
 
.00 (-.01, .00) 
 
.041 
 
Minority x Other Risk Exposure 
 
-.78 (-.15, -.06) 
 
.035 
 
Minority x Depression Symptoms 
 
-.08 (-.13, -.04) 
 
<.001 
 
R2 = .14 
Note. Nonsignificant interactions are not included in the final model. 
 
1.7 What factors are associated with healthcare provider distrust by HIV+ 
patients? 
1.8 Do the factors associated with healthcare provider distrust by HIV+ 
patients vary by racial/ethnic minority status? 
 
Table 5.6 shows the unadjusted bivariate associations between healthcare provider distrust 
and potential sociodemographic and psychosocial factors. Higher distrust scores were associated 
with younger age, having completed college, less annual income, being exposed to HIV through 
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injection drug use, higher viral load, poorer physical and mental health, more symptoms of 
depression and dysthymia, using any type of illicit drug in the past year, less social support, and 
more discriminatory healthcare experiences. 
 
Table 5.6. Bivariate Associations between Healthcare Provider Distrust  
and Potential Sociodemographic and Psychosocial Factors  
 
 Healthcare Provider Distrust 
 β (95% CI) p 
 
Minority 
 
.05 (-.05, .15) 
 
.288 
 
Female 
 
-.02 (-.09, .05) 
 
.639 
 
Age 
 
-.04 (-.06, -.02) 
 
<.001 
 
Education 
     High School 
     Less than College 
     College or Higher 
     Less than High School 
 
 
-.03 (-.09, .03) 
.07 (-.03, .17) 
-.08 (-.17, .00) 
 
 
.373 
.144 
.046 
 
Annual Income 
 
-.04 (-.06, -.02) 
 
<.001 
 
Insurance Status  
    Medicaid 
    Medicare 
    Private 
    None 
 
 
.04 (-.05, .13) 
-.06 (-.13, .01) 
-.01 (-.09, .06) 
(reference) 
 
 
.339 
.098 
.715 
 
Sexual Orientation 
    Heterosexual 
    Bisexual 
    Homosexual 
 
 
-.02 (-.09, .04) 
.02 (-.07, .13) 
(reference) 
 
 
.483 
.563 
 
Risk Exposure 
    IDU 
    Male-to-Female Sexual Contact 
    Other 
    Male-to-Male Sexual Contact 
 
 
.10 (.02, .17) 
-.04 (-.10, .03) 
-.01 (-.14, .12) 
(reference) 
 
 
.016 
.256 
.841 
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 Healthcare Provider Distrust 
 β (95% CI) p 
 
Year Diagnosed HIV+ 
 
.00 (-.01, .01) 
 
.871 
 
AIDS Diagnosis 
 
-.03 (-.12, .05) 
 
.472 
 
Viral Load 
 
.03 (.02, .04) 
 
<.001 
 
Lowest Ever CD4 Count 
 
.02 (-.02, .07) 
 
.253 
 
Self-Perceived Physical Health 
 
-.01 (-.02, -.01) 
 
<.001 
 
Self-Perceived Mental Health  
 
-.02 (-.02, -.01) 
 
<.001 
 
Depression Symptoms 
 
.02 (.01, .03) 
 
<.001 
 
Dysthymia Symptoms 
 
.05 (.04, .07) 
 
<.001 
 
Type of Drug Used in Past Year 
     Marijuana or Analgesics 
     Inhalants, Hallucinogens, Sedatives, or Amphetamines 
     Heroin or Cocaine 
     No Use 
 
 
.10 (.03, .17) 
.11 (.02, .19) 
.17 (.07, .27) 
(reference) 
 
 
.004 
.018 
.001 
 
Usual HIV Provider 
 
-.11 (-.25, .04) 
 
.139 
 
Social Support 
 
.00 (-.01, .00) 
 
<.001 
 
Discriminatory Healthcare Experiences 
 
.06 (.04, .08) 
 
<.001 
Note. Because of missing data, the sample sizes across items range from 1890 to 2263. 
 
Multivariate associations between healthcare provider distrust, baseline sociodemographic 
characteristics, and discriminatory healthcare experiences are shown in Table 5.7. Because 
distrust scores did not vary by minority status, an interaction analysis was not performed. Higher 
distrust scores were associated with younger age, having some college education, higher viral 
load, poorer physical and mental health, using any illicit drug in the past year except heroin and 
cocaine, and less social support. More discriminatory healthcare experiences were also 
  61 
independently associated with greater healthcare provider distrust, so Hypothesis 1.8 was 
supported. These variables explained 12% of the variance in distrust scores. 
Table 5.7. Multivariate Model of Healthcare Provider Distrust (n = 1866) 
 
 Healthcare Provider Distrust 
 β (95% CI) p 
 
Age 
 
-.04 (-.07, -.01) 
 
.009 
 
Less than College 
 
.12 (.03, .21) 
 
.012 
 
College 
 
.05 (-.06, .16) 
 
.363 
 
Annual Income 
 
.01 (-.02, .03) 
 
.572 
 
Medicare 
 
-.04 (-.10, .03) 
 
.261 
 
IDU Risk Exposure 
 
.05 (-.03, .13) 
 
.180 
 
Viral Load 
 
.02 (.00, .03) 
 
.022 
 
Self-Reported Physical Health 
 
.00 (-.01, .00) 
 
.042 
 
Self-Reported Mental Health  
 
-.01 (-.01, -.01) 
 
<.001 
 
Depression Symptoms 
 
.00 (-.02, .01) 
 
.573 
 
Dysthymia Symptoms 
 
-.01 (-.03, .01) 
 
.203 
 
Used Marijuana or Analgesics in Past Year 
 
.07 (-.01, .14) 
 
.071 
 
Used Inhalants, Hallucinogens, Sedatives, or 
Amphetamines in Past Year 
 
.09 (.01, .16) 
 
.024 
 
Used Heroin or Cocaine in Past Year 
 
.08 (-.04, .19) 
 
.190 
 
Usual HIV Provider 
 
-.03 (-.16, .09) 
 
.617 
 
Social Support 
 
.00 (.00, .00) 
 
<.001 
 
Discriminatory Healthcare Experiences 
 
.04 (.02, .06) 
 
.001 
 
R2 =  .12 
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5.2. AIM 2 
To test a causal model of the relationships among racial/ethnic minority status, 
discriminatory healthcare experiences, healthcare provider distrust, 
antiretroviral therapy attitudes and beliefs, and antiretroviral therapy adherence. 
 
5.2.1. Sample Description 
Table 5.8 presents descriptive statistics for the sample for Aim 2 (n = 1911) stratified by 
racial/ethnic minority status. Compared to nonminorities, minority participants were more likely 
to be female, have less than a high school degree, earn less than $25,000, have no insurance or 
Medicaid, have been exposed to HIV through male-to-female sexual contact, have used heroin 
or cocaine in the past year.  Minorities were less likely than nonminorities to identify as 
homosexual and have an AIDS diagnosis. Minority participants also reported less social support 
than nonminority participants. Compared to minorities, nonminority participants had been 
diagnosed with HIV infection longer, had a lower viral load, and were less likely to ever have a 
CD4 count less than 200. Nonminority participants also had more symptoms of depression but 
fewer symptoms of dysthymia, and took more antiretroviral medications; the magnitude of those 
differences, however, was small. 
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Table 5.8. Sample Characteristics for Aim 2 by Minority Status 
 
 Minority 
(n=918), 
% or Mean (SD) 
Nonminority 
(n=993), 
% or Mean (SD) 
 
 
p 
 
Female 
 
32.8 
 
12.1 
 
<.001 
 
< 35 Years Old 
 
24.5 
 
29.8 
 
.064 
 
< High School Degree 
 
35.0 
 
11.8 
 
<.001 
 
< $25,000 Annual Income 
 
83.7 
 
53.5 
 
<.001 
 
Insurance in Last 6 Months 
     None 
     Medicaid 
     Medicare 
     Private 
 
 
19.1 
39.8 
18.8 
22.4 
 
 
14.3 
16.4 
2.7 
48.7 
 
 
<.001 
 
 
Sexual Orientation 
     Homosexual 
     Heterosexual 
     Bisexual 
 
 
28.3 
62.3 
8.9 
 
 
68.7 
24.9 
6.3 
 
 
<.001 
 
 
Risk Exposure 
     Injection Drug Use 
     Male/Female Sexual Contact 
     Male-to-male sexual contact 
     Other 
 
 
25.7 
33.4 
3.2 
1.7 
 
 
18.7 
66.5 
9.2 
5.6 
 
 
<.001 
 
 
Year First Tested HIV-Positive  
 
1992 (3.1) 
 
1990 (3.4) 
 
<.001 
 
Has AIDS Diagnosis 
 
56.8 
 
64.1 
 
.017 
 
Viral Load < 1000 copies/ml 
 
27.9 
 
38.9 
 
<.001 
 
Lowest Ever CD4 Count < 200  
 
28.8 
 
21.2 
 
<.001 
 
Self-Perceived Physical Health 
 
5.1 (9.8) 
 
5.1 (9.8) 
 
.895 
 
Self-Perceived Mental Health  
 
5.3 (1.0) 
 
5.3 (9.8) 
 
.960 
 
Depression Symptoms 
 
1.6 (2.8) 
 
1.9 (3.0) 
 
.005 
 
Dysthymia Symptoms 
 
1.0 (1.6) 
 
.7 (1.4) 
 
<.001 
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 Minority 
(n=918), 
% or Mean (SD) 
Nonminority 
(n=993), 
% or Mean (SD) 
 
 
p 
 
Used Heroin or Cocaine in Past Year 
 
17.7 
 
11.5 
 
<.001 
 
Number of Antiretroviral Medications 
 
2.8 (.7) 
 
3.0 (.7) 
 
<.001 
 
Has Usual HIV Provider 
 
91.8 
 
91.9 
 
.967 
 
Social Support 
 
62.8 (27.8) 
 
68.8 (28.3) 
 
<.001 
 
5.2.2. Statistics Describing Antiretroviral Therapy Adherence 
Almost half of the participants (45.7%, n = 888) reported perfect adherence to antiretroviral 
therapy in the past week. Minority participants were less likely to report perfect adherence than 
nonminority participants (40.3% [CI95: 35.9%, 44.7%] vs. 45.3% [CI95: 46.1%, 54.5%], χ
2 [1, 54] 
= 31.5, p < .001). Table 5.9 presents regression coefficients representing the unadjusted bivariate 
associations between the degree of antiretroviral therapy adherence and its covariates. Better 
antiretroviral adherence was associated with older age, having a high school degree or more, 
higher income, better physical and mental health, taking more antiretroviral medications, and 
greater social support. Poorer adherence was associated with minority status, female gender, 
having Medicaid, heterosexual orientation, exposure to HIV through injecting drug use or male-
to-female sexual contact, higher viral load, more symptoms of depression and dysthymia, and 
using heroin or cocaine in the past year.7 These variables were used as covariates in subsequent 
analyses. 
 
                                                 
7 Further analyses did not identify problems with collinearity among the proposed covariates. 
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Table 5.9. Bivariate Associations among Antiretroviral Therapy Adherence and  
Control Variables (n = 1911) 
 
 Antiretroviral  
Therapy Adherence 
 β (95% CI) p 
 
Minority 
 
-.32 (-.42, -.22) 
 
<.001 
 
Female 
 
-.31 (-.40, -.23) 
 
<.001 
 
Age 
 
.01 (.01, .01) 
 
<.001 
 
Highest Degree 
     High School/GED 
     Associate’s  
     Bachelor’s or Higher 
     Less than High School 
 
 
.28 (.14, .42) 
.22 (.04, .41) 
.40 (.25, .56) 
(reference) 
 
 
<.001 
.020 
<.001 
 
Annual Income  
 
.09 (.06, .12) 
 
<.001 
 
Insurance Status  
    Medicaid 
    Medicare 
    Private 
    None 
 
 
-.31 (-.46, -.16) 
-.02 (-.15, .10) 
.11 (-.02, .25) 
(reference) 
 
 
<.001 
.730 
.093 
 
Sexual Orientation 
    Heterosexual 
    Bisexual 
    Homosexual 
 
 
-.26 (-.37, -.16) 
-.07 (-.18, .04) 
(reference) 
 
 
<.001 
.197 
 
Risk Exposure 
    IDU 
    Male-to-Female Sexual Contact 
    Other 
    Male-to-Male Sexual Contact 
 
 
-.20 (-.32, -.08) 
-.30 (-.43, -.18) 
-.05 (-.18, .09) 
(reference) 
 
 
.002 
<.001 
.484 
 
Year Diagnosed HIV+  
 
.00 (-.01, .01) 
 
.943 
 
AIDS Diagnosis  
 
.07 (-.02, .15) 
 
.112 
 
Viral Load 
 
-.05 (-.09, -.02) 
 
.003 
 
Lowest Ever CD4 Count  
 
.04 (.03, .11) 
 
.290 
 
Self-Perceived Physical Health  
 
.02 (.01, .02) 
 
<.001 
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 Antiretroviral  
Therapy Adherence 
 β (95% CI) p 
 
Self-Perceived Mental Health  
 
.02 (.01, .02) 
 
<.001 
 
Depression Symptoms 
 
-.02 (-.04, -.01) 
 
.009 
 
Dysthymia Symptoms 
 
-.09 (-.13, -.04) 
 
<.001 
 
Type of Illicit Drugs Used in Past Year 
     Marijuana or Analgesics 
     Inhalants, Hallucinogens, Sedatives, or Amphetamines 
     Heroin or Cocaine 
     No Use 
 
 
-.10 (-.21, .01) 
-.14 (-.30, .02) 
-.20 (-.32, -.08) 
(reference) 
 
 
.085 
.094 
.002 
 
Number of Antiretroviral Medications 
 
.12 (.05, .20) 
 
.003 
 
Usual HIV Provider 
 
.16 (-.04, .37) 
 
.117 
 
Social Support 
 
.00 (.00, .00) 
 
.002 
 
 
5.2.3. Structural Equation Models 
I tested hypotheses regarding mediators of the relationship between racial/ethnic minority 
status and antiretroviral therapy adherence using structural equation modeling (SEM). The 
measurement model for SEM, created by confirmatory factor analysis, is the hypothesized 
relationships between observed indicators and factors. The structural model for SEM produces 
estimates (beta weights) of the strength and direction of relationships among factors. The overall 
fit of a proposed model to data is assessed through fit indices, whose results are compared to 
published guidelines. Model fit is improved by adding or deleting paths based on content 
knowledge and modification indices reported by the MPlus statistical program. When the model 
fit was satisfactory, I trimmed nonsignificant paths from the model. The following sections 
provide the results of this process. 
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5.2.3.1. Measurement Model 
Confirmatory factor analysis (CFA) established the measurement models for subsequent 
analyses, i.e., confirmed the hypothesized structure of study constructs (latent variables). CFA 
was conducted separately for discriminatory healthcare experiences, healthcare provider distrust, 
antiretroviral therapy attitudes and beliefs, and antiretroviral therapy adherence. Table 5.11 
presents the factor loading estimates and squared multiple correlations of construct indicators.8 
Factor loading estimates are regression coefficients, with their standardized form interpretable as 
Pearson correlation coefficients between indicators and constructs (Kline, 2005). The critical 
ratios for factor loadings were all above 1.96 and therefore statistically significant at p < .05. The 
standardized factor loadings were all greater than .50, a large effect according to Cohen’s (1988) 
typology. The squared multiple correlations of the indicators denote the proportion of variance 
explained by the construct (Kline, 2005). Two indicators had squared multiple correlations of .40 
or less: refused service (REFUSE; .34) and number of days took lesser amount of medication 
than prescribed (rLESS; .35). These indicators were retained, however, because of their 
conceptual importance.  
Table 5.10 also presents the fit indices for the final measurement models of the key study 
variables. As a reminder, both measurement and structural models are considered to have a good 
fit if: the ratio of χ2 to degrees of freedom (CMINDF) is 3.0 or less; the weighted root mean 
residual (WRMR) is 1.00 or less; the root mean square error of approximation (RMSEA) is .06 
or less; and the Tucker-Lewis (TLI), and Comparative Fit (CFI) indices are .95 or greater.9 The 
fit indices generally suggest that the measurement models demonstrated adequate to good fit. 
The ratios for χ2 to degrees of freedom (CMINDF) are well over the preferred score of 3.0 for 
                                                 
8 Observations with missing data on multiple construct indicators were dropped from further analysis (n = 25). 
  
9 Model fit is assessed in the context of values from a set of indices and no one index provides a gold standard.  
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Healthcare Provider Distrust, Antiretroviral Therapy Attitudes and Beliefs, and Antiretroviral 
Therapy Adherence, which indicate poor fit. The values for the other four goodness-of-fit 
indices, however, described earlier meet the suggested guidelines. Therefore, I deemed the 
measurement models satisfactory and proceeded to test the structural model (relationships 
among constructs).  
 
Table 5.10. Confirmatory Factor Analyses of Study Constructs (n = 1886) 
 
Construct 
 
Indicator (Label) Unstd 
Factor 
Loading 
Std 
Factor 
Loading 
R2 
 
 
Exhibited hostility or a lack of respect to 
participant  (HOSTILE)*  
 
1.00 
 
.65 
 
.43 
 
Gave less attention to participant than to other 
patients (LESSATTEN) 
 
1.01 
 
.66 
 
.44 
 
Refused service to participant (REFUSE) 
 
.89 
 
.58 
 
.34 
 
Was uncomfortable with participant 
(UNCOMF) 
 
1.40 
 
.91 
 
.84 
 
Treated participant as inferior (INFERIOR) 
 
1.46 
 
.96 
 
.92 
 
Preferred to avoid participant (AVOID) 
 
1.50 
 
.98 
 
.96 
 
Discriminatory 
Healthcare 
Experiences 
 
 
Model Fit: χ2 = 8.91, df = 3, p = .030;  
CMINDF = 2.97; CFI = 1.00; TLI = 1.00;  
RMSEA = .03; WRMR = .48 
   
 
Trust to offer quality care (QUALITY) * 
 
1.00 
 
.90 
 
.81 
 
Trust to know best treatments (BEST) 
 
.88 
 
.80 
 
.63 
 
Trust to give enough information (INFO) 
 
.99 
 
.89 
 
.80 
 
Trust to keep personal information private 
(PRIVATE) 
 
.86 
 
.78 
 
.60 
 
Healthcare 
Provider 
Distrust 
 
 
Trust to treat patient nonjudgmentally 
(NOTJUDGE) 
 
.95 
 
.86 
 
.74 
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Construct 
 
Indicator (Label) Unstd 
Factor 
Loading 
Std 
Factor 
Loading 
R2 
 
 
 
Trust to offer high quality care regardless of 
insurance coverage (INSUR) 
 
 
.95 
 
 
.86 
 
 
.74 
 
Trust to put patient needs ahead of research 
goals (RESEARCH) 
.92 .83 .68 
 
Model Fit: χ2 = 47.29, df = 4, p = .000;  
CMINDF = 11.82; CFI = .99; TLI = .99;  
RMSEA = .08; WRMR = .92 
   
 
Antiretroviral Therapy Attitudes and Beliefs** 
   
 
Too many pills to take (PILLS) * 
 
1.00 
 
.79 
 
.51 
 
Wanted to avoid side effects (EFFECT) 
 
1.04 
 
.82 
 
.75 
 
Reminded self of HIV status (HIV) 
 
.88 
 
.69 
 
.57 
 
Health wasn’t improving (HEALTH) 
 
1.00 
 
.78 
 
.62 
 
Felt the drug was too toxic (TOXIC) 
 
1.07 
 
.84 
 
.62 
 
Worried about becoming immune (IMMUNE) 
 
1.01 
 
.80 
 
.67 
 
Took a “drug holiday” (HOLIDAY) 
 
.97 
 
.76 
 
.48 
 
Psychological 
Burden of 
Medication 
 
 
Felt depressed or overwhelmed (DEPRESS) 
 
 
1.02 
 
.81 
 
.61 
Hard to get HIV medications (HARD) * 1.00 .74 .67 
 
Easy to get HIV prescriptions (EASY) 
 
.93 
 
.69 
 
.71 
 
Takes a lot of time and effort to get HIV 
medication (TIME) 
 
1.03 
 
.76 
 
.64 
Difficulty 
Accessing 
Medication 
 
 
HIV medication would be hard to get if it runs 
out (RUNOUT) 
 
 
.87 
 
.64 
 
.58 
Away from home (AWAY) * 1.00 .75 .65 
 
Too busy or forgot (BUSY) 
 
1.05 
 
.79 
 
.54 
Difficulty 
Scheduling 
Medication 
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Construct 
 
Indicator (Label) Unstd 
Factor 
Loading 
Std 
Factor 
Loading 
R2 
 
Change in daily routine (CHANGE) .87 .64 .47 
 
HIV medications make people live longer 
(LONGER) * 
 
1.00 
 
.71 
 
.57 
 
HIV medications improve the quality of 
people’s lives (IMPROVE) 
 
1.22 
 
.87 
 
.41 
 
Medication 
Efficacy Beliefs 
 
 
Model Fit: χ2 = 42.93, df = 9, p = .000; 
CMINDF = 4.77; CFI = .99; TLI = .98;  
RMSEA = .05; WRMR = 1.29 
   
 
#Days forgot to take a dose – reverse 
(rFORGOT) * 
 
1.00 
 
.71 
 
.50 
 
#Days purposely skipped dose – reverse 
(rSKIP) 
 
.88 
 
.58 
 
.33 
 
#Days took lesser amount – reverse (rLESS) 
 
.85 
 
.60 
 
.36 
 
#Days took as prescribed (PERFECT) 
 
2.10 
 
.86 
 
.74 
 
Took meds exactly as prescribed (GLOBAL) 
 
1.07 
 
.67 
 
.45 
 
Antiretroviral 
Therapy 
Adherence 
 
 
Model Fit: χ2 = 27.19, df = 2, p = .000;  
CMINDF = 13.60; CFI = .98; TLI = .98;  
RMSEA = .08; WRMR = .54 
   
*These parameters were constrained to 1.00 to scale the constructs. 
**The constructs that comprise Antiretroviral Therapy Attitudes and Beliefs were tested as a group because they were 
hypothesized to covary. 
Note: All factor loadings were significant at p < .05; however, constrained indicators were not tested. 
 
Figures 5.1, 5.2, and 5.3 present the final measurement models. Circles represent constructs 
(factors, or latent variables). Squares represent indicators (or observed variables). Single-headed 
arrows from constructs (circles) to indicators (squares) represent standardized factor loadings. 
Single-headed arrows into indicators (squares) represent residual variance, or error. Double-headed 
arrows between constructs (circles) represent covariances; and double-headed arrows between the 
residual variances of indicators (single-headed arrows into squares) represent correlated 
measurement error that I suggest is due to similar item wording.  
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Figure 5.1. Standardized Measurement Model of Discriminatory Healthcare 
Experiences, All Factor Loadings Significant at p < .05 
 
 
Figure 5.2. Standardized Measurement Model of Healthcare Provider Distrust,  
All Factor Loadings Significant at p < .05 
 
 
Healthcare 
Provider 
Distrust 
Quality Best Info Private Not 
Judge 
Insur 
Research 
.90 .80 .89 .78 .86 .86 
.83 
 
Discriminatory 
Healthcare 
Experiences 
Hostile Less 
Atten 
Refuse Uncomf Inferior Avoid 
.65 .66 .58 .91 .96 .98 
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Figure 5.3. Standardized Measurement Model of Antiretroviral Therapy Beliefs and 
Attitudes, All Factor Loadings Significant at p < .05 
Pills 
Effect 
HIV 
Health 
Toxic 
Immune 
Holiday 
Depress 
Hard 
rEasy 
Time 
RunOut 
Away 
Busy 
Change 
Longer 
Improve 
Psychological 
Burden of 
Medication 
Difficulty 
Accessing 
Medication 
Difficulty 
Scheduling 
Medication 
Medication 
Efficacy 
Beliefs 
.79 
.82 
.69 
.78 
.84 
.80 
.76 
.81 
.74 
.69 
.76 
.64 
.75 
.79 
.64 
.71 
.87 
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Figure 5.4. Standardized Measurement Model of Antiretroviral Therapy Adherence,  
All Factor Loadings Significant at p < .05 
 
 
Table 5.11 presents bivariate correlations, means, and standard deviations of the study 
constructs produced with the composite variables used in Aim 1. Poorer antiretroviral therapy 
adherence was associated with greater healthcare provider distrust and all antiretroviral therapy 
attitudes and beliefs. Discriminatory healthcare experiences were not associated with poorer 
adherence. Both discriminatory healthcare experiences and healthcare provider distrust were 
associated with greater psychological burden of medication, difficulty accessing medications, 
difficulty scheduling medications, and more negative beliefs about medication efficacy.  
 
 
Antiretroviral 
Therapy 
Adherence 
rForgot rSkip rLess Perfect Global 
.71 .58 .60 .86 .67 
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Table 5.11. Correlations, Means, and Standard Deviations (n = 1886) 
 
 1 2 3 4 5 6 7 
 
1. Antiretroviral Therapy Adherence 
 
 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Discriminatory Healthcare  
    Experiences 
 
-.03 
.198 
 
-- 
 
 
 
 
 
 
 
 
 
 
 
 
3. Healthcare Provider Distrust 
 
-.09 
<.001 
 
.16 
<.001 
 
-- 
 
 
 
 
 
 
 
 
 
 
4. Psychological Burden of Medication 
 
-.47 
<.001 
 
.11 
<.001 
 
.22 
<.001 
 
-- 
 
 
 
 
 
 
 
 
5. Difficulty Accessing Medication 
 
-.10 
<.001 
 
.06 
.011 
 
.12 
<.001 
 
.15 
<.001 
 
-- 
 
 
 
 
 
 
6. Difficulty Scheduling Medication 
 
-.43 
<.001 
 
.09 
<.001 
 
.16 
<.001 
 
.43 
<.001 
 
.14 
<.001 
 
-- 
 
 
 
 
7. Medication Efficacy Beliefs 
 
-.15 
<.001 
 
.10 
<.001 
 
.20 
<.001 
 
.25 
<.001 
 
.16 
<.001 
 
.13 
<.001 
 
-- 
 
 
Mean 
 
6.40 
 
1.19 
 
1.46 
 
1.37 
 
2.18 
 
1.91 
 
1.53 
 
S.D. 
 
.92 
 
1.8 
 
.60 
 
.55 
 
.39 
 
.78 
 
.52 
 
 
5.2.3.2. Structural Model 
Table 5.12 summarizes the fit indices of the original and modified mediation models. By all 
of the goodness-of-fit indices except for the root mean square error of approximation 
(RMSEA), the original mediation model presented in Figure 5.5 (χ2 = 76.02, df = 12, p = .000) 
was a poor fit for the data. Guided by modification indices and conceptual plausibility, I 
sequentially added parameters to improve the fit of the model.  
No literature directly supports the following modifications that add paths among 
antiretroviral therapy attitudes and beliefs, but the new paths can be justified logically. First, I 
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added a direct path from Psychological Burden of Disease to Difficulty Scheduling Medication 
(Mod 1). It is possible that patients who have concerns about or negative associations with 
antiretroviral therapy may have more difficulty incorporating the medication into their daily 
routine. Second, I added a direct path from Medication Efficacy Beliefs to Difficulty Accessing 
Medication (Mod 2). It is possible that patients who believe antiretroviral therapy is less 
important to their health may believe that the difficulty they go through to obtain the medication 
is more trouble than it’s worth. Third, I added a direct path from Medication Efficacy Beliefs to 
Psychological Burden of Medication (Mod 3). It is possible that patients who believe 
antiretroviral therapy is less important to their health may also have more concerns about or 
negative associations with the medication. Finally, I allowed the errors of all of the Antiretroviral 
Therapy Adherence indicators except for GLOBAL to covary (i.e., to have a relationship) 
because of possible measurement error due to similar wording.  
The built up model presented in Figure 5.6 (χ2 = 40.87, df = 12, p = .000) demonstrated 
good fit across the CFI, TLI, and RMSEA indices and adequate fit for CMINDF and WRMR. 
The model was then trimmed to remove nonsignificant paths; these included paths from: 
Minority Status to Difficulty Accessing Medication; Discriminatory Healthcare Experiences to 
Antiretroviral Therapy Adherence; and Difficulty Accessing Medication to Antiretroviral 
Therapy Adherence. Figure 5.7 presents the final trimmed model (χ2 = 40.48, df = 12, p = .000) 
with standardized parameters; additional details about parameter estimates follows.  
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Table 5.12. Measures of Overall Fit for Original and Modified Structural Models 
 
 χ2  
(df, p) 
CMINDF CFI TLI RMSEA WRMR 
 
Original 
 
76.02 
(12, .000) 
 
6.34 
 
.92 
 
.91 
 
.05 
 
1.94 
 
Mod 1: Added path 
from Psychological 
Burden to Difficulty 
Scheduling 
 
53.20 
(12, .000) 
 
4.43 
 
.95 
 
.94 
 
.04 
 
1.61 
 
Mod 2: Added path 
from Medication 
Efficacy to Difficulty 
Accessing 
 
47.68 
(12, .000) 
 
3.97 
 
.96 
 
.95 
 
.04 
 
1.52 
 
Mod 3: Added path 
from Medication 
Efficacy to 
Psychological Burden 
 
45.68 
(12, .000) 
 
3.81 
 
.96 
 
.95 
 
.04 
 
1.48 
 
Mod 4: Added error 
covariances among 
Adherence indicators 
 
40.87 
(12, .000) 
 
3.41 
 
.97 
 
.96 
 
.04 
 
1.39 
 
Final: Dropped 
nonsignificant  paths 
 
40.48 
(12, .000) 
 
3.37 
 
.97 
 
.96 
 
.04 
 
1.40 
Note. CMINDF = ratio of χ2 to degrees of freedom; CFI = Comparative Fit Index; TLI = Tucker-Lewis Index; 
RMSEA = root means square error of approximation; WRMR = weighted root mean residual
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Figure 5.5. Original Structural Model 
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Therapy 
Adherence 
  
7
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Figure 5.6. Structural Model after Modifications 
 
Mod 2 
Racial/ 
Ethnic 
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Provider 
Distrust 
Discriminatory 
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Difficulty 
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Figure 5.7. Final Trimmed Structural Model with Adjusted Standardized Parameter Estimates, All Significant at p < .05 
 
Racial/ 
Ethnic 
Minority 
Status 
Healthcare 
Provider 
Distrust 
Discriminatory 
Healthcare 
Experiences 
Psychological 
Burden of 
Medication 
Difficulty 
Accessing 
Medication 
Difficulty 
Scheduling 
Medication 
 
Weak Medication 
Efficacy Beliefs 
 
Antiretroviral 
Therapy 
Adherence 
-.43 
.15 .15 
.32 
-.21 
.14 
.09 
.16 
.06 
.56 
-.29 
-.36 
.20 
 .50 
 .13 
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The next section reviews evidence that discriminatory healthcare experiences, healthcare 
provider distrust, and antiretroviral therapy attitudes and beliefs mediate the relationship 
between racial/ethnic minority status and antiretroviral therapy adherence. 
 
2.1 Is racial/ethnic minority status associated with antiretroviral therapy 
adherence? 
 (H 2.1.1.) Racial/ethnic minority HIV+ patients will have poorer adherence to antiretroviral 
therapy than nonminority HIV+ patients. 
 
2.2 Do discriminatory healthcare experiences partially mediate the 
relationship between racial/ethnic minority status and antiretroviral 
therapy adherence? 
  (H 2.2.1) As discriminatory healthcare experiences increases, adherence to antiretroviral 
therapy decreases. 
 (H 2.2.2) Minority HIV+ patients will have more discriminatory healthcare experiences and, 
in turn, poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
 
2.3 Does healthcare provider distrust partially mediate the relationship 
between racial/ethnic minority status and antiretroviral therapy 
adherence? 
(H 2.3.1) As healthcare provider distrust increases, adherence to antiretroviral therapy  
decreases. 
  (H 2.3.2) Minority HIV+ patients will have greater distrust in their healthcare providers 
and, in turn, poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
 
2.4 Do antiretroviral therapy attitudes and beliefs partially mediate the 
relationship between racial/ethnic minority status and antiretroviral 
therapy adherence? 
 (H 2.4.1) As (a) psychological burden of medication increases, (b) difficulty accessing 
medication, (c) difficulty scheduling medication, and (d) negative beliefs about medication efficacy 
increases, antiretroviral therapy adherence decreases. 
(H 2.4.2) Minority HIV+ patients will have more difficulty accessing medication and, in 
turn, poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
(H 2.4.3) Minority HIV+ patients will have more negative beliefs in medication efficacy and, 
in turn, poorer adherence to antiretroviral therapy than nonminority HIV+ patients. 
 
Table 5.13 presents the regression weights, covariances, and residual variances of the final 
model (Figure 5.7) along with the squared multiple correlations for the latent variables. The 
reported standardized parameter estimates (b) are adjusted for factors associated with 
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antiretroviral therapy adherence. As a reminder, these estimates are significant at the p < .05 
level when the absolute value of the critical ratio (t) is greater than 1.96. In the table, the 
regression weight under the “Parameter” column represents the coefficient estimates of the path 
through which the first factor affects the second factor. For example, “Minority → 
Discriminatory Healthcare Experiences” indicates the direct effect of racial/ethnic minority 
status on discriminatory healthcare experiences. The covariances represent nondirectional 
associations between item error terms. The residual variances are error terms for both the 
factors and items. The R2 of each factor is listed under “Residual Variances” as well. 
Hypothesis 2.1.1 was supported; racial/ethnic minority patients had poorer antiretroviral 
adherence than nonminority patients (β = -.12, t = -3.29). Hypothesis 2.2.1 was not supported; 
discriminatory healthcare experiences were not associated with adherence, and thus were not 
included in the final trimmed model. Hypothesis 2.3.1 was not supported as HIV+ patients who 
were more distrustful of their healthcare providers had better antiretroviral adherence than 
patients who were less distrustful of their healthcare providers (β = .04, t = 2.88), which was 
contrary to the hypothesized direction. Most antiretroviral therapy attitudes and beliefs had 
direct effects on antiretroviral therapy adherence. The exception was Difficulty Accessing 
Medication, whose path was dropped in the final model and therefore Hypothesis 2.4.1b was not 
supported. The parameter estimate for Medication Efficacy Beliefs had a positive instead of 
negative sign. Therefore, Hypothesis 2.4.1d was also not supported (nor Hypothesis 2.4.3 by 
extension; but see discussion of indirect effects).  
As reported for Aim 1, racial/ethnic minority HIV + patients reported fewer discriminatory 
healthcare experiences than nonminority patients (β = -.39, t = -3.95). There was no direct effect 
of racial/ethnic minority status on Difficulty Accessing Medication, whose path was dropped in 
the final model. Thus the hypothesized mediating effects of Discriminatory Healthcare 
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Experiences and Difficulty Accessing Medication on the relationship between racial/ethnic 
minority status and antiretroviral therapy adherence were not supported (Hypothesis 2.2.2 and 
2.4.2). Contrary to the results from the unadjusted bivariate analyses of Aim 1, racial/ethnic 
minority patients had greater distrust for their healthcare providers than nonminority patients in 
this multivariate analysis (β = .14, t = 2.14). Racial/ethnic minority patients also had more 
negative beliefs about the efficacy of antiretroviral therapy than did nonminority patients (β = 
.25, t = 4.67).  
There were other unhypothesized direct effects among study constructs, such as the path 
from Discriminatory Healthcare Experiences to Medication Efficacy Beliefs (β = .12, t = 3.94), 
and the path from Healthcare Provider Distrust to Medication Efficacy Beliefs (β = .13, t = 
3.18). The final trimmed model explained almost half the variance of antiretroviral therapy 
adherence (R2 = .49), with the squared multiple correlations of individual constructs ranging 
from .15 for Healthcare Provider Distrust to .58 for Psychological Burden of Medication. 
 
Table 5.13. Variance-Adjusted Weighted Least Squares Parameter Estimates  
of the Final Structural Model (n = 1867)  
 
Parameter Unstd 
Estimate* 
Std 
Error 
Std 
Estimate* 
t 
 
Regression Weights 
    
 
Minority → Discriminatory Healthcare Experiences 
 
-.39 
 
.10 
 
-.43 
 
-3.95 
 
Minority → Healthcare Provider Distrust 
 
.14 
 
.07 
 
.15 
 
2.14 
 
Minority → Medication Efficacy Beliefs 
 
.25 
 
.05 
 
.32 
 
4.67 
 
Minority → Antiretroviral Therapy Adherence 
 
-.12 
 
.04 
 
-.21 
 
-3.29 
 
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust 
 
.15 
 
.04 
 
.14 
 
3.84 
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Parameter Unstd 
Estimate* 
Std 
Error 
Std 
Estimate* 
t 
 
Discriminatory Healthcare Experiences →  
Medication Efficacy Beliefs 
 
.12 
 
.03 
 
.14 
 
3.94 
 
Healthcare Provider Distrust →  
Psychological Burden of Medication 
 
.08 
 
.02 
 
.09 
 
3.30 
 
Healthcare Provider Distrust →  
Medication Efficacy Beliefs 
 
.13 
 
.04 
 
.16 
 
3.18 
 
Healthcare Provider Distrust →  
Antiretroviral Therapy Adherence 
 
.04 
 
.01 
 
.06 
 
2.88 
 
Psychological Burden of Medication →  
Difficulty Scheduling Medication 
 
.52 
 
.03 
 
.56 
 
15.59 
 
Psychological Burden of Medication →  
Antiretroviral Therapy Adherence 
 
-.18 
 
.02 
 
-.29 
 
-8.69 
 
Difficulty Scheduling Medication →  
Antiretroviral Therapy Adherence 
 
-.25 
 
.02 
 
-.36 
 
-16.25 
 
Medication Efficacy Beliefs →  
Psychological Burden of Medication 
 
.22 
 
.04 
 
.20 
 
5.94 
 
Medication Efficacy Beliefs →  
Difficulty Accessing Medication 
 
.49 
 
.06 
 
.50 
 
8.34 
 
Medication Efficacy Beliefs →  
Antiretroviral Therapy Adherence 
 
.09 
 
.04 
 
.13 
 
2.34 
 
Covariances 
    
 
Antiretroviral Therapy Adherence:  
Error (rSKIP) ↔ Error (rFORGOT) 
 
-.11 
 
.01 
 
-.11 
 
-8.00 
 
Antiretroviral Therapy Adherence:  
Error (rSKIP) ↔ Error (PERFECT) 
 
.21 
 
.02 
 
.21 
 
10.09 
 
Antiretroviral Therapy Adherence:  
Error (rLESS) ↔ Error (rFORGOT) 
 
.07 
 
.01 
 
.07 
 
7.90 
 
Residual Variances 
    
 
Discriminatory Healthcare Experiences (R2 = .18)  
 
.67 
 
.04 
 
.83 
 
17.51 
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Parameter Unstd 
Estimate* 
Std 
Error 
Std 
Estimate* 
t 
 
Healthcare Provider Distrust (R2 = .15) 
 
.79 
 
.01 
 
.85 
 
55.03 
 
Psychological Burden of Medication (R2 = .39) 
 
.48 
 
.03 
 
.61 
 
16.66 
 
Difficulty Accessing Medication (R2 = .33) 
 
.40 
 
.03 
 
.67 
 
11.84 
 
Difficulty Scheduling Medication (R2 = .46) 
 
.37 
 
.02 
 
.54 
 
18.27 
 
Medication Efficacy Beliefs (R2 = .37) 
 
.38 
 
.04 
 
.63 
 
9.54 
 
Antiretroviral Therapy Adherence (R2 = .49) 
 
.16 
 
.01 
 
.51 
 
15.39 
 
Antiretroviral Therapy Adherence:  
Error (rFORGOT) 
 
.44 
 
.01 
 
.44 
 
37.77 
 
Antiretroviral Therapy Adherence: Error (rSKIP) 
 
.56 
 
.02 
 
.56 
 
32.70 
 
Antiretroviral Therapy Adherence: Error (rLESS) 
 
.55 
 
.01 
 
.55 
 
38.93 
 
Antiretroviral Therapy Adherence:  
Error (PERFECT) 
 
.88 
 
.04 
 
.88 
 
24.44 
*Controlling for gender, age, education, annual income, insurance status, HIV risk behavior, self-reported physical 
and mental health, depression, dysthymia, type of illicit drug used in the past year, number of antiretroviral 
medications, social support, and adherence self-efficacy.  
 
 
The total, direct, and indirect effects of racial/ethnic minority status on antiretroviral therapy 
adherence are presented in Table 5.14. The direct effect is the parameter estimate of the 
relationship between one construct and the outcome. Indirect effects are parameter estimates of 
mediating pathways. The total effect is the sum of the direct and indirect effects. In the table, the 
first two lines note the total and direct effects of racial/ethnic minority status on antiretroviral 
therapy adherence. The labels in the “Mediating Path” column represent the indirect effects of 
racial/ethnic minority status on antiretroviral therapy adherence. For example, “Discriminatory 
Healthcare Experiences → Healthcare Provider Distrust” indicates the path from racial/ethnic 
minority status to discriminatory healthcare experiences to healthcare provider distrust to 
antiretroviral therapy adherence. 
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There were a total of nine significant indirect effects of racial/ethnic minority status on 
antiretroviral therapy adherence: six via Discriminatory Healthcare Experiences; one via 
Healthcare Provider Distrust; and two via Medication Efficacy Beliefs. The strongest indirect 
effects came through Medication Efficacy Beliefs (β = .02, t = 2.06) and the path between 
Medication Efficacy Beliefs and Psychological Burden of Medication (β = -.01, t = -3.29). These 
two indirect effects also accounted for the largest proportion of the total effect of racial/ethnic 
minority status on antiretroviral therapy adherence (11.7%). Although these indirect pathways 
were statistically significant, the magnitudes of these effects were negligible. The direct effect is 
essentially the same as the total effect, indicating lack of mediation from the hypothesized 
factors. Therefore, I consider Hypotheses 2.3.2 and 2.4.3 to be unsupported. 
 
Table 5.14. Direct, Total, and Indirect Effects of Racial/Ethnic Minority Status on 
Antiretroviral Therapy Adherence via Hypothesized Mediators (n = 1867) 
 
Mediating Path Unstd 
Estimate* 
Std  
Error 
Std 
Estimate* 
t 
 
Total Effect of Minority Status 
 
-.111 
 
.031 
 
-.199 
 
-3.57 
 
Direct Effect of Minority Status 
 
-.117 
 
.036 
 
-.209 
 
-3.29 
 
Via Discriminatory Healthcare Experiences 
 
    
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust  
 
-.002 .001 -.004 -3.07 
Discriminatory Healthcare Experiences →  
Medication Efficacy Beliefs 
 
-.004 .002 -.008 -1.91 
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust →  
Psychological Burden of Medication  
 
.001 <.001 .001 2.44 
Discriminatory Healthcare Experiences →  
Medication Efficacy Beliefs →  
Psychological Burden of Medication 
.002 .001 .003 2.14 
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Mediating Path Unstd 
Estimate* 
Std  
Error 
Std 
Estimate* 
t 
 
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust →  
Medication Efficacy Beliefs 
 
-.001 <.001 -.001 -1.52 
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust →  
Medication Efficacy Beliefs →  
Psychological Burden of Medication 
 
<.001 <.001 .001 2.07 
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust →  
Psychological Burden of Medication →  
Difficulty Scheduling Medication  
 
.001 <.001 .001 2.15 
Discriminatory Healthcare Experiences →  
Medication Efficacy Beliefs →  
Psychological Burden of Medication →  
Difficulty Scheduling Medication 
 
.001 .001 .002 1.92 
Discriminatory Healthcare Experiences →  
Healthcare Provider Distrust →  
Medication Efficacy Beliefs →  
Psychological Burden of Medication →  
Difficulty Scheduling Medication 
<.001 <.001 <.001 2.19 
Subtotal: 
% of Total Effect: 
 
-.002 
1.8 
   
 
Via Healthcare Provider Distrust 
 
    
Healthcare Provider Distrust 
 
.005 .003 .009 1.62 
Healthcare Provider Distrust →  
Psychological Burden of Medication 
 
-.002 .001 -.004 -1.60 
Healthcare Provider Distrust →  
Medication Efficacy Belief 
 
.002 .001 .003 1.29 
Healthcare Provider Distrust →  
Medication Efficacy Belief →  
Psychological Burden of Medication 
 
-.001 <.001 -.001 -1.64 
Healthcare Provider Distrust →  
Psychological Burden of Medication →  
-.007 .003 -.013 -2.90 
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Mediating Path Unstd 
Estimate* 
Std  
Error 
Std 
Estimate* 
t 
Difficulty Scheduling Medication 
 
Healthcare Provider Distrust →  
Medication Efficacy Beliefs →  
Psychological Burden of Medication →  
Difficulty Scheduling Medication 
-.001 <.001 -.001 -1.84 
Subtotal: 
% of Total Effect: 
 
-.004 
3.6 
   
 
Via Medication Efficacy Beliefs 
 
    
Medication Efficacy Beliefs 
 
.023 .011 .042 2.06 
Medication Efficacy Beliefs → 
Psychological Burden of Medication 
-.010 .003 -.019 -3.29 
Subtotal: 
% of Total Effect: 
.013 
11.7 
   
*Controlling for gender, age, education, annual income, insurance status, HIV risk behavior, self-reported physical 
and mental health, depression, dysthymia, type of illicit drug used in the past year, number of antiretroviral 
medications, social support, and adherence self-efficacy.  
 
5.3 SUMMARY 
 This chapter presented the results of multiple regression and SEM analyses examining the 
relationships among racial/ethnic minority status, discriminatory healthcare experiences, 
healthcare provider distrust, antiretroviral therapy attitudes and beliefs, and antiretroviral therapy 
adherence. Table 5.15 summarizes the support for study hypotheses provided by these results. 
In the final chapter, I discuss the findings in the context of existing research and consider 
potential next steps for research and practice. 
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Table 5.15. Summary of Support for Study Hypotheses 
 
Hypothesis Support 
 
(H 1.2) Minority HIV+ patients will have more discriminatory healthcare 
experiences than nonminority HIV+ patients.  
 
 
No 
(H 1.4) More minority HIV+ patients will distrust their healthcare provider than 
nonminority HIV+ patients.  
 
No 
(H 2.1.1.) Racial/ethnic minority HIV+ patients will have poorer adherence to 
antiretroviral therapy than nonminority HIV+ patients. 
 
Yes 
(H 2.2.1) As discriminatory healthcare experiences increases, adherence to 
antiretroviral therapy decreases. 
 
No 
(H 2.2.2) Minority HIV+ patients will have more discriminatory healthcare 
experiences and, in turn, poorer adherence to antiretroviral therapy than 
nonminority HIV+ patients. 
 
No 
(H 2.3.1) As healthcare provider distrust increases, adherence to antiretroviral 
therapy decreases. 
 
No 
 
(H 2.3.2) Minority HIV+ patients will have greater distrust in their healthcare 
providers and, in turn, poorer adherence to antiretroviral therapy than nonminority 
HIV+ patients. 
 
 
Partial 
(H 2.4.1) As (a) psychological burden of medication,  
(b) difficulty accessing medication,  
(c) difficulty scheduling medication, and  
(d) negative beliefs about medication efficacy increase, antiretroviral therapy 
adherence decreases. 
 
Yes 
No 
Yes 
No 
(H 2.4.2) Minority HIV+ patients will have more difficulty accessing medication 
and, in turn, poorer adherence to antiretroviral therapy than nonminority HIV+ 
patients. 
 
No 
(H 2.4.3) Minority HIV+ patients will have more negative beliefs in medication 
efficacy and, in turn, poorer adherence to antiretroviral therapy than nonminority 
HIV+ patients. 
 
No 
 
 
 
 
 
 
CHAPTER SIX: 
DISCUSSION 
 
In this study I assessed the prevalence and factors associated with discriminatory healthcare 
experiences and healthcare provider distrust, two indicators of interpersonal care quality, and 
their effects on antiretroviral adherence by HIV+ patients. The first two sections of the chapter 
interpret key findings by study aim in the context of existing research. The third section 
describes the study’s limitations, strengths, and significance. The chapter concludes with 
suggestions for future research and implications for practice. 
 
6.1. SUMMARY OF AIM 1 
Given the dearth of research in this area, the study’s first aim was to describe the prevalence 
and factors associated with discriminatory healthcare experiences and healthcare provider 
distrust among HIV+ patients.  
6.1.1. Discriminatory Healthcare Experiences  
Prevalence. Almost half (41%) the HIV+ patients studied reported ever experiencing 
discrimination in healthcare settings. This is a 60% higher prevalence than the 26% prevalence 
reported by Schuster and colleagues (2005) using the same HIV Cost and Services Utilization 
Study (HCSUS) dataset. The discrepancy in rates could be due to differences in the 
operationalization of discrimination. Schuster and colleagues (2005) measured discrimination 
with four indicators of discriminatory healthcare experiences at the first follow-up interview 
(been uncomfortable with the patient, treated the patient as an inferior, preferred to avoid the 
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patient, or refused service to the patient). The present study measured discrimination using six 
indicators, three from the baseline (exhibited hostility or lack of respect towards patient, gave 
less attention than to other patients, refused service to patient) and three from the first follow-
up interview (been uncomfortable with the patient, treated the patient as an inferior, preferred to 
avoid the patient). This expanded measure was used to capture more domains of discriminatory 
healthcare experiences than those used in the Schuster study.  
The wider range of potential types of discrimination may have increased the likelihood that 
HIV+ patients surveyed had experienced at least one of those situations. Bird and colleagues 
(2004), for example, reported a much higher prevalence of discriminatory healthcare experiences 
(71%) among HIV+ individuals who responded to a list of seven potentially discriminatory 
experiences: treated patient with less courtesy than shown to other people; treated patient with 
less respect than other people; provided poorer service than to others; thought patient was not 
smart; acted as if afraid of patient; acted as if better than patient; did not listen to what patient 
was saying. Participants were asked whether they attributed being a recipient of these negative 
experiences to their race and/or socioeconomic status, for a total of 14 potential discriminatory 
healthcare experiences. The present study, on the other hand, did not separately consider 
discrimination by reported stigmatizing characteristic (e.g., HIV status, sexual orientation) in 
because of the small sample sizes associated with characteristics other than HIV status. In 
addition, the indicators used in the study by Bird and colleagues (2004) referred to interactions 
with HIV+ patients’ current healthcare providers (specifically their physician), while indicators 
used in the present study referred to any interaction with a healthcare provider (e.g., physician, 
nurse, dentist) since the time the patient had been diagnosed with HIV. The exposure variables 
used in the present study may have been more liable to recall bias and thus less sensitive 
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indicators of the prevalence of discriminatory healthcare experiences than variables that referred 
to interactions with a current provider.  
In both this and the Schuster (2005) study, white HIV+ patients reported more 
discriminatory healthcare experiences than did racial/ethnic minority HIV+ patients in a 
national sample. In contrast, Bird and colleagues (2004) found no differences in discrimination 
by racial/ethnic minority status among HIV+ individuals. Research on non-HIV specific 
samples generally finds that racial/ethnic minority participants report more unfair treatment by 
healthcare providers than do whites, regardless of the perceived cause (Lillie-Blanton et al., 2000; 
Perez, 2005; Piette et al., 2006). One study using a national sample found that racial/ethnic 
differences in perceived disrespect and condescension from physicians were explained after 
adjusting for patient characteristics, source of care, and patient-physician communication 
measures (Johnson et al., 2004). Possible explanations for the unexpected findings reported here, 
and in the previous study using the HCSUS data (Schuster et al., 2005), are several. First, white 
participants had been diagnosed with HIV longer than their racial/ethnic minority peers, thus 
providing the white sample with more opportunities to experience, remember, and report 
healthcare discrimination. Second, racial/ethnic minority participants experiencing 
discrimination may have minimized or taken perceived prejudicial treatment for granted. On the 
contrary, white male participants, who were predominantly gay in this sample, may not have 
been open about their sexual orientation before 1996, and hence not exposed to any 
discrimination their homosexuality may have evoked from their healthcare providers prior to 
their HIV diagnosis (Hayter, 1996; Klitzman & Greenberg, 2002).  
Factors. Many factors associated with discriminatory healthcare experiences by HIV+ patients 
were related to these participants’ health status, consistent with other research on discriminatory 
healthcare experiences among HIV+ patients (Bird et al., 2004; Kass et al., 1992; Schuster et al., 
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2005). These factors – earlier diagnosis of HIV, poorer self-reported health, having an AIDS 
diagnosis, and ever having a CD4 count less than 200 – suggest that sicker individuals may be 
more likely to experience the effects of HIV/AIDS stigma in healthcare settings. Early in the 
epidemic several visible indicators of advanced HIV infection, such as the dark lesions of 
Karposi’s sarcoma or wasting syndrome, signaled AIDS to the general public (Shilts, 1987; 
Weiner et al., 1988). Physical manifestations of disease are classic markers of stigma, exposing 
people to more frequent discrimination (Goffman, 1963; Weiner et al., 1988). Furthermore, the 
longer individuals have been diagnosed with HIV or the more often they have been sick, the 
more opportunities they have to experience, and report, discrimination.  
Other factors associated with discriminatory healthcare experiences by HIV+ patients 
included younger age, having some college education, use of any type of illicit drug in the past 
year except heroin or cocaine, and reporting less social support. Besides education, earlier studies 
of discriminatory healthcare experiences among HIV+ patients have not investigated these 
factors. In this study, racial/ethnic minority status interacted with two other factors, HIV risk 
exposure and depression symptoms, of discriminatory healthcare experiences. However, these 
interaction terms did not increase the explanatory power of the discriminatory healthcare 
experience multivariate model. In fact, the sociodemographic factors in this study explained only 
a small proportion of the variance of discriminatory healthcare experiences. Future research 
should explore other psychosocial factors (e.g., stigma consciousness, group identity, coping) 
and contextual variables (e.g., high poverty, low physician to population ratio) unavailable in this 
dataset that may be more strongly associated with discrimination. 
6.1.2. Healthcare Provider Distrust 
Prevalence. Although discriminatory healthcare experiences were common in this study, 
healthcare provider distrust was not. Across domains, few participants expressed distrust of their 
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healthcare providers. The overall level of healthcare provider distrust in this sample did not vary 
by racial/ethnic minority status, contrary to the study hypothesis. Other researchers have also 
found high levels of trust in personal healthcare providers by HIV+ patients (Altice et al., 2001; 
Golin et al., 2002; Ingersoll & Heckman, 2005; Schneider et al., 2004; Whetten et al., 2006). The 
lack of racial/ethnic difference in healthcare provider distrust is consistent with previous smaller 
studies of HIV+ patients, but not with national studies on provider distrust conducted in the 
general population (Boulware et al., 2003; Corbie-Smith et al., 2002; Doescher et al., 2000; 
Schnittker, 2004; Taira et al., 2001). In the present study, the only racial/ethnic difference across 
trust domains was concern that healthcare providers would place research goals above 
participants’ personal interests. This finding is consistent with other research which has reported 
African Americans in particular to be skeptical of medical researchers’ intentions and the 
benefits of medical research to them personally and as a group (Allen et al., 2005; Corbie-Smith, 
Thomas, Williams, & Moody-Ayers, 1999). The difference in healthcare provider distrust 
between racial/ethnic groups on this domain was small, however, with overlapping confidence 
intervals and thus may not be of great importance in understanding differences that occur when 
individual HIV+ patients interact with individual healthcare providers. In the face of a life-
threatening illness, both racial/ethnic minority and white HIV+ patients may simply trust more 
instinctively those who provide critical medical care.  
Factors. The factors associated with healthcare provider distrust among HIV+ patients 
overlap some with those of discriminatory healthcare experiences. Both psychosocial constructs 
are associated with younger age, having attained some college education, poorer self-reported 
health, drug use in the past year, and less social support. In addition, greater healthcare provider 
distrust was also associated with higher viral load, poorer mental health, and experiencing more 
discrimination in healthcare settings. Previous studies of HIV+ patients have not explored 
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factors associated with healthcare provider distrust, so comparisons with such studies are not 
possible. However, research with non-HIV specific samples did not find or has not examined 
associations between healthcare provider distrust and age, drug use, or social support, but did 
find relationships with poorer health status and less education (Doescher et al., 2000; Schnittker, 
2004). The inclusion of drug use (a stigmatizing behavior) and social support are psychosocial 
stressors and buffers that may affect HIV+ patients’ expectations about their healthcare 
providers. As with discriminatory healthcare experiences, the hypothesized sociodemographic 
factors of distrust supported by these analyses explained little of the variance of healthcare 
provider distrust among HIV+ patients. Also, potentially important psychosocial and contextual 
factors of healthcare provider distrust were not available in the public use HCSUS dataset.  
6.1.3. Racial/Ethnic Minority Status and Interpersonal HIV/AIDS Care Quality 
 
The extent of discriminatory healthcare experiences and healthcare provider distrust in this 
sample does not provide evidence of racial/ethnic disparities in the quality of interpersonal 
HIV/AIDS care. Earlier research in the general population has suggested that experiences, 
expectations, and beliefs about racism in healthcare would lead racial/ethnic minority patients to 
perceive more discrimination (regardless of the source to which they attributed the 
discrimination), as well as report more distrust in their healthcare providers. Either these effects 
do not exist among minority participants, or they are being overshadowed by the effects of 
HIV/AIDS stigma shared by all participants.  
 
6.2. SUMMARY OF AIM 2 
The study’s second aim was to test a model of the direct and indirect effects of racial/ethnic 
minority status, discriminatory healthcare experiences, and healthcare provider distrust on 
antiretroviral adherence by HIV+ patients. Many studies, although not all, have found that 
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racial/ethnic minority HIV+ patients report poorer antiretroviral therapy adherence than white 
HIV+ patients (Bogart et al., 2004; Gifford et al., 2000; Golin et al., 2002; Gordillo et al., 1999; 
van Servellen et al., 2002). Thus, the primary objective was to examine possible mediators of an 
observed relationship between racial/ethnic minority status and adherence. The full model with 
covariates explained almost half (49%) the variance found in participants’ self-reported 
adherence to antiretroviral therapy.  
6.2.1. Racial/Ethnic Minority Status  
 
Contrary to the study’s hypotheses, the observed relationship between racial/ethnic minority 
status and antiretroviral therapy adherence was not mediated by discriminatory healthcare 
experiences, healthcare provider distrust, or antiretroviral therapy attitudes and beliefs. The 
structural equation modeling analyses identified several statistically significant pathways 
involving one or more of the hypothesized mediators (specifically discriminatory healthcare 
experiences, healthcare provider distrust, and medication efficacy beliefs), but the magnitude of 
each indirect effect was negligible (generally less than .01) and the sum of these effects was not 
statistically significant. The fact that racial/ethnic minority status remained, in multivariate 
models, significantly associated with adherence in the present study can be understood in the 
context of fundamental cause theory. That theory posits that the effects of social and economic 
inequity cannot be eliminated by addressing the mechanisms that appear to link them to disease 
(Link & Phelan, 1995). If true, the direct effect of racial/ethnic minority status (a crude proxy 
for the effects of racism) on antiretroviral therapy adherence would not be completely mediated 
by discrimination, distrust, or medication beliefs. However, I had hypothesized that there would 
be evidence of partial mediation. One explanation for the lack of either partial mediation may be 
that important factors (e.g., housing stability, shared decisionmaking) have been left out of the 
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analysis. Given the large number of included covariates, however, it is unlikely that the bias from 
one or two potential omitted variables would dramatically affect the findings reported here. 
6.2.2. Discriminatory Healthcare Experiences 
 
The effect of discriminatory healthcare experiences on antiretroviral therapy adherence in 
this sample was entirely indirect, contrary to study hypotheses. The indirect effects occurred 
when participants’ distrust of their healthcare providers increased and their beliefs in the worth 
of antiretroviral therapy weakened. Discriminatory healthcare experiences may subtly color 
HIV+ patients’ perspectives on their care providers and the treatment they recommend. This 
finding contrasts with the findings of the only other study to examine these relationships (Bird et 
al., 2004). Bird and colleagues (2004) found that discrimination based on socioeconomic status, 
but not on racial/ethnic minority status, was associated with antiretroviral therapy adherence. 
That analysis was conducted on a small convenience sample (n = 110) of participants recruited 
through an AIDS service organization in the Midwest and examined only bivariate correlates of 
adherence. The current study had a large national sample, did not differentiate between the 
attributions made for discriminatory healthcare experiences (e.g., HIV status versus racial/ethnic 
minority status), and controlled for multiple covariates of antiretroviral therapy adherence. On 
the basis of the larger sample size and multivariate analysis, the present study offers stronger 
evidence that discriminatory healthcare experiences do not directly influence antiretroviral 
therapy adherence.  
6.2.3. Healthcare Provider Distrust 
 
As hypothesized, healthcare provider distrust has both direct and indirect effects on 
antiretroviral therapy adherence. The relationship between distrust and adherence is consistent 
with multivariate findings in previous studies of antiretroviral therapy adherence (Altice et al., 
2001; Schneider et al., 2004), but the direction of the effect was unexpected. In focus groups and 
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interviews, HIV+ patients have drawn connections between the trust they have in their 
healthcare providers and their willingness to comply with treatment recommendations (Roberts, 
2002; Stone et al., 1998): “If you don’t trust your doctor, you won’t trust (and take) your meds” 
(Roberts, 2002). The results of the present study seem to indicate the opposite: that negative 
expectations of their healthcare providers may increase HIV+ patients’ resolve and 
determination to comply with a demanding treatment regimen. In a related study, Ford (2005) 
found that African American STD clinic patients who perceived more racism were more likely 
to get tested for HIV. HIV+ patients in the present study, as in Ford’s, may feel that their 
healthcare providers are not looking out for their best interests. Hence, they must be extra 
vigilant about the care that they receive.  
The indirect effects of healthcare provider distrust occurred as a result of increases in 
participants’ psychological distress about having to take antiretroviral therapy and of weakened 
beliefs in the worth of antiretroviral therapy. Previous research has not specifically examined the 
extent to which healthcare provider distrust influences treatment-related attitudes and beliefs. 
Because the indicators of healthcare provider distrust and antiretroviral therapy attitudes and 
belief used in this analysis were measured at the same point in time, it is possible that the effect 
occurred in the opposite direction. That is, participants’ negative feelings about antiretroviral 
therapy may have increased their distrust in their healthcare providers for encouraging use of the 
regimen in the first place. Both interpretations are plausible.  
6.2.4. Other Effects 
Other findings of note relate to the associations, or lack thereof, among hypothesized 
mediators. First, the difficulty participants had fitting antiretroviral therapy into their daily lives 
showed the strongest direct effect on self-reported antiretroviral therapy non-adherence. Being 
able to take ones’ medications despite disruptions is a key task for HIV+ patients, and is 
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consistently associated with antiretroviral therapy adherence (Chesney, 2003). Second, contrary 
to the study hypothesis, participants’ perceptions that antiretroviral therapy is difficult to obtain 
was not significantly associated with adherence in the final model. The inclusion of financial 
resources (indicated by annual income and insurance status) and social support as control 
variables may explain this finding. Finally, being a member of a racial/ethnic minority group was 
associated with greater healthcare provider distrust in the structural equation model explaining 
variation in antiretroviral therapy adherence but not in the multiple regression model of 
healthcare provider distrust in Aim 1 that included primarily sociodemographic factors. This 
unexpected finding may indicate a suppressor effect, where an independent variable is 
significantly associated with the outcome variable only in the presence of a third variable 
(MacKinnon, Lockwood, Hoffman, West, & Sheets, 2002). In this case, racial/ethnic differences 
in healthcare provider distrust may only appear when controlling for the effects of other 
psychosocial factors, in this case antiretroviral therapy attitudes and beliefs.  
6.2.5. Alternative Model 
Although a strong conceptual and empirical rationale underlies the proposed mediation 
model, it is possible that racial/ethnic minority status might, instead, moderate the relationships 
among other study constructs. A moderation model would suggest that the stigma of 
racial/ethnic minority status (racism) produces different contexts for antiretroviral therapy 
adherence among racial/ethnic minority and nonminority HIV+ patients. That is, the effect of 
discriminatory healthcare experiences and healthcare provider distrust on antiretroviral therapy 
attitudes, beliefs, and adherence may be stronger among racial/ethnic minority patients than 
nonminority patients. These relationships may also be affected by the different environments in 
which the two groups of HIV+ patients in the present study live, demonstrated by the 
sociodemographic characteristics of the sample. For example, racial/ethnic minority patients in 
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this sample were younger, less educated, poorer, and more likely to have been exposed to HIV 
through injection drug use or male/female sexual contact than were nonminority participants. 
The two groups may have had different priorities, concerns, and resources when it came to 
antiretroviral therapy adherence. In this alternative explanation, racial/ethnic minority status is a 
contextual, rather than an exogenous, variable in models of antiretroviral therapy adherence.  
6.2.6. Stigma, Interpersonal Care Quality, and Antiretroviral Therapy Adherence 
These findings offer partial support for the relationships, based on attribution theory, 
posited among discriminatory healthcare experiences, healthcare provider distrust, and 
antiretroviral therapy adherence. Racial/ethnic minority status, as a proxy for expectations and 
experiences with racism in healthcare, was negatively associated with healthcare provider distrust 
but not discriminatory healthcare experiences. Discriminatory healthcare experiences were 
positively associated with healthcare provider distrust, but only indirectly influenced the 
behavioral outcome of adherence. Distrust, the negative expectations of healthcare providers, 
was unexpectedly associated with antiretroviral therapy adherence. These results generally 
support other research that has found subtle effects of patient-provider relationships on 
treatment adherence (DiMatteo & DiNicola, 1982; Hall, Roter, & Katz, 1988; Roter & Hall, 
1993).  
 
6.3. STUDY LIMITATIONS, STRENGTHS, AND SIGNIFICANCE 
6.3.1. Limitations  
Context of the Sample. The present study’s findings are the product of data collected over 10 
years ago, and as such, are probably less generalizable to HIV+ individuals in care today. The 
HIV Cost and Services Utilization Study was conducted when antiretroviral therapy was just 
coming into widespread use. Previously considered a death sentence, these medications ushering 
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in a new era of the HIV/AIDS epidemic in the United States and produced great optimism 
among people living with HIV at the time (Kagawa-Singer, 2000; Kelly & Kalichman, 2002; 
Kelly, Otto-Salaj, Sikkema, Pinkerton, & Bloom, 1998). While such an optimistic context may 
have positively influenced participants’ attitudes and beliefs about antiretroviral therapy, and 
thus motivation to adhere, the regimens at the time were very complex. Although the number of 
antiretroviral medications taken has sometimes been associated with poorer adherence (Chesney, 
2003; Fogarty et al., 2002), it was not a significant factor in the present study. In the years since 
the HCSUS data was conducted new medications that have been developed, including simpler 
twice-daily and even single-dose regimens (Giordano, 2006). The differences in both general 
patient optimism and complexity of available medication regimens may lessen the 
generalizeability of these study findings to the current population of HIV+ patients.  
Attrition and Selection Biases. Certain characteristics of the study sample may influence the 
interpretation and generalizability of these findings. Participants who completed all three waves 
of data collection were more likely than those who did not do so to have been white, exposed to 
HIV through male/female sexual contact, not have an AIDS diagnosis, not be heroin or cocaine 
users, and have more social support10. In addition, participants who were prescribed 
antiretroviral therapy at the second follow-up interview were more likely than those who were 
not to have had higher incomes, higher viral loads, an AIDS diagnosis, and distrust their 
healthcare providers less. These attrition and selection biases produced a more homogeneous 
study sample compared to the full HCSUS sample and may reduce the generalizability of the 
findings to the general population of HIV+ individuals in care. These biases may also have 
                                                 
10 Almost all of the sociodemographic variables were collected at baseline, but all of the indicators of healthcare 
provider distrust used in the present study were collected at the second follow-up interview. Thus only participants 
who completed all three waves of data collection answered these questions.  
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underestimated the effect of discriminatory healthcare experiences and healthcare provider 
distrust on antiretroviral therapy adherence (only assessed at the second follow-up interview). 
Social Desirability and Recall Biases. HIV+ patients may under-report the number of times they 
fail to take their medications as prescribed because of a desire to appear compliant (and hence 
socially acceptable) in the eyes of their physicians (Chesney, 2003; Liu et al., 2001; Miller & Hays, 
2000; Turner, 2002). On the other hand, Wagner and Miller (2004) found that poor memory, not 
concern about provider reactions, was the main reason that HIV+ patients in a pilot study did 
not disclose missing medications. Indeed, four of the five adherence indicators were based on a 
mean score across up to 14 medications. The effect of either social desirability or recall bias may 
be to underestimate the relationships between study constructs and antiretroviral adherence. 
Measurement Issues. Except for healthcare provider distrust (Kao et al., 1998), key measures 
were newly developed for the present study and thus not previously validated. They were not 
formally tested for invariance (psychometric equivalence) by racial/ethnic minority status, but 
they demonstrated good reliability and other satisfactory psychometric properties across groups 
(data not shown). Another limitation is the degree to which other researchers might agree about 
how these measures were constructed or interpreted. For example, Williams and colleagues 
(2003) point toward the stress literature to argue that inventories of discriminatory experiences 
should not be considered as indicators of the underlying construct, and that high internal 
consistency suggests redundancy or wording bias, not validity. For these researchers, the fact 
that a person experiences one type of discrimination does not necessarily imply the likelihood of 
having another. In contrast, I would argue that theories of attribution (Harvey & Weary, 1984; 
Kelley & Michela, 1980) as well as other social psychological constructs such as cognitive 
schemas support an underlying factor related to the way that individuals perceive and interpret 
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problematic interpersonal interactions. The proper interpretation of the measures, as well as 
their validity, will not be settled in one study.  
Temporality. The HIV Cost and Services Utilization Study collected three waves of data over 
approximately a 12 month period; the present study used measures from each wave. However, 
the indicators for healthcare provider distrust, antiretroviral therapy attitudes and beliefs, 
adherence, and a few covariates were only collected at the second follow-up interview. In this 
way, therefore, the design is primarily cross-sectional and cannot establish causality among these 
constructs. The research design leaves unclear whether healthcare provider distrust precedes 
negative attitudes towards antiretroviral therapy or vice versa.  
The indicators for discriminatory healthcare experiences were obtained at baseline and the 
first follow-up interview and thus have some claim on temporal order. How recent these 
experiences occurred, however, is unknown as participants were asked to recall incidents “since 
they had HIV”— which could be one month to ten years prior to the study. This variability 
would have the effect of reducing the strength of association between discriminatory healthcare 
experiences and the other factors. 
Between versus Within Group Analysis. I categorized all members of racial/ethnic minority 
groups as part of one group for these analyses because sample sizes among some subpopulations 
(Asian/Pacific Islanders and Native Americans) would be too small to analyze. I did not exclude 
these groups because the focus of the study was the ways that interpersonal care quality and 
healthcare outcomes were affected by racism (stigma). Membership in a racial/ethnic minority 
group indicates a subordinate social status in the U.S. which, through the processes of stigma 
(Link & Phelan, 1995), implies a history of oppression or experience of discrimination (Jones, 
2001; LaVeist, 1994; Williams, 1997). The small sizes of some subpopulations in HCSUS are 
likely to have made little difference to the study findings had these groups been excluded. 
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However, the different racial/ethnic minority groups undoubtedly have unique life experiences 
and circumstances that may or may not affect their healthcare and health outcomes (Williams, 
1997). Subgroup analyses might have revealed different prevalences, predicators, and patterns of 
associations among discriminatory healthcare experiences, healthcare provider distrust, and 
antiretroviral therapy adherence. For example, members of Asian and Pacific Islander groups 
often report significantly poorer interpersonal care from healthcare providers than do members 
of other groups, but these experiences are not generally associated with poorer healthcare 
outcomes (Ngo-Metzger, Legedza, & Phillips, 2004; Taira et al., 2001). Future examination of 
how these processes work within subpopulations may lead to a more nuanced understanding of 
what differentiates those who have better and worse outcomes (Corbie-Smith et al., 2004; 
Kagawa-Singer, 2000).  
6.4.2. Strengths and Significance 
Choice of Dataset. Although the unique temporal context of the HIV Cost and Services 
Utilization Study may have reduced the generalizability of my conclusions, several characteristics 
of the sample make it useful for research on interpersonal care quality and healthcare outcomes. 
It remains the only large, multiethnic national study of which I am aware of that includes 
measures of both discriminatory healthcare experiences and healthcare provider distrust. In 
addition, the large sample allowed for the detection of small effects that may be important at the 
population, if not at the individual, level.  
Analytic Technique. Another strength of this analysis is the use of structural equation 
modeling. Although the technique does not establish the right or “true” model, it does allow for 
the testing of hypotheses about direct and indirect effects. Multiple and multi-part pathways for 
mediators have not been explicitly considered in previous research on antiretroviral therapy 
adherence. In addition, the analysis of latent variables takes measurement error and bias from 
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omitted variables into account, producing estimates that are less biased than regression analyses 
of observed variables which assume that independent variables are measured without error. 
Examined Potential Mechanisms of Racial/Ethnic Healthcare Disparities.  This research contributes 
to the emerging literature on racism and healthcare, as opposed to health, outcomes. In this 
study, I attempted to address the recommendations of earlier investigators who call for more 
research into the potential pathways by which racial/ethnic healthcare disparities are produced 
(Corbie-Smith et al., 2004; Lurie, 2002; Smedley et al., 2003). I used social psychological and 
sociological theories to conceptualize relationships among the key study constructs. Although 
the results did not fully support my hypotheses, this research adds to our understanding of how 
individual-level sociodemographic and psychosocial factors influence healthcare outcomes by 
racial/ethnic minority and nonminority HIV+ patients.  
 
6.5. AREAS OF FUTURE RESEARCH AND IMPLICATIONS FOR PRACTICE 
There is no cure for the disease, but receipt of appropriate, timely, and high quality medical 
care can reduce HIV/AIDS-related morbidity and mortality (Bozzette et al., 2000; Centers for 
Disease Control and Prevention, 2002). Current quality improvement efforts among federally-
funded HIV/AIDS treatment programs focus on clinical indicators such as increased use of 
antiretroviral therapy and controlled HIV viral loads (Bozzette et al., 2000; Landon et al., 2004; 
McKinney et al., 2002). Experts recognize, however, that the quality of interpersonal HIV/AIDS 
care medical personnel provide may affect achievement of desired healthcare outcomes 
(McKinney et al., 2002). Specifically, increasing the quality of care and improving outcomes for 
racial/ethnic minority HIV+ patients, as well as white HIV+ patients, will require more 
attention to interpersonal care issues (Stone, 2004). The next sections present possible areas of 
future research and potential implications for practice that are suggested by this study’s findings. 
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6.5.1. Future Research 
Refinement and further assessment of study measures are critical areas for future research. 
First, research on how these measures are understood by participants and perform 
psychometrically will help to establish their validity. Qualitative, formative work, such as 
cognitive interviewing might clarify to what extent HIV+ patients identify and differentiate 
between categories of discriminatory experiences, domains of healthcare provider (dis)trust, and 
types of antiretroviral therapy attitudes and beliefs. Second, researchers should conduct 
confirmatory factor analyses with samples of HIV+ patients and the general public to 
corroborate the form of the measures used in this study, as well as assess psychometric 
differences across racial/ethnic groups (invariance). Finally, researchers could compare the 
predictive power of lifetime experiences of healthcare experiences to measures of discriminatory 
experiences with patients’ current providers.  
Improvements and extensions to the study design and analyses are other fruitful areas of 
future research. First, designing longitudinal studies with the temporality of measures in mind 
will help to better tease apart the direction of effect among hypothesized psychosocial factors 
and adherence, the behavioral outcome. Second, researchers should refine and extend the model 
proposed in this study. Instead of using racial/ethnic minority status as a proxy for experiences 
and expectations of racism in healthcare, for example, analyses should incorporate measures of 
beliefs in medical racism and generalized healthcare distrust. In addition, the current analyses 
controls for, as opposed to parceling out, provider-level effects on HIV+ patients’ assessments 
of interpersonal care quality. Multilevel modeling would allow researchers to explore the extent 
that provider factors such as racial/ethnic minority status, gender, and experience/expertise 
both working with HIV patients and in medicine overall contribute to the variability in 
discriminatory healthcare experiences, healthcare provider distrust and, ultimately, antiretroviral 
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therapy adherence. Finally, as described earlier, future research should compare the mediation 
model proposed in this study with one that considers racial/ethnic minority status as a 
moderator, or contextual, factor. These areas of future research will further our understanding of 
both racial/ethnic disparities in interpersonal care quality as well as in antiretroviral therapy 
adherence. 
6.5.2. Practice Implications 
The findings of this study raise questions about whether and how healthcare providers take 
their patients’ racial/ethnic minority status into account within the clinical encounter. Evidence 
exists that healthcare providers are more likely to stereotype racial/ethnic minority patients as 
nonadherent to treatment regimens than they do white patients (Balsa & McGuire, 2003; Bogart, 
Catz, Kelly, & Benotsch, 2001; Lutfey & Ketcham, 2005). That is, providers have a priori beliefs 
that racial/ethnic minority patients will not adhere to treatment recommendations more 
frequently than white patients. Such beliefs may influence clinical decision making and, 
consciously or not, worsen the quality of interpersonal care (Smedley et al., 2003; van Ryn, 
2002). Early stereotypes about nonadherence may have affected treatment patterns of 
racial/ethnic minority HIV+ patients (Bogart et al., 2001; Stone, 2006). As a result some 
researchers discourage the use racial/ethnic minority status as a heuristic for predicting of 
antiretroviral therapy adherence by HIV+ patients (Chesney, 2003; Stone, 2004; Stone, 2006l 
Turner, 2002). The present study and others, however, did not find that the relationship between 
racial/ethnic minority status and antiretroviral therapy adherence was explained by patient-level 
sociodemographic or psychosocial factors. How can these divergent points of view be 
reconciled?  
One possible approach may include increased patient-centeredness by healthcare providers 
that acknowledges, but does not prioritize, the possible role of racial/ethnic minority status as an 
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influence on interpersonal care quality. Patient-centered healthcare providers must manage a 
delicate balance between considering their patients’ beliefs, needs, and choices and 
understanding the social context in which those individual circumstances occur. For 
racial/ethnic minority patients, this context may produce experiences and expectations of racism 
in healthcare that may influence judgment about their care and care providers. Members of other 
stigmatized groups such as HIV+ individuals may similarly have experiences or expectations of 
discrimination in healthcare settings. This study’s patient-level analysis implies patient-level 
interventions such as education and empowerment strategies. The interaction between patients 
and providers that produces patient assessments of interpersonal care quality, however, suggests 
a need to intervene at the provider level as well. As each clinical encounter produces 
expectations of the next (Goold, 2002; Keating et al., 2002; LaVeist et al., 2000), such 
interventions should target both generic clinical and cross-cultural communication skills. Better 
communication and relationships between HIV+ patients and their healthcare providers may 
help improve antiretroviral therapy adherence for all patients and also help reduce disparities by 
racial/ethnic minority status. 
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APPENDIX A: 
EXPLORATORY FACTOR ANALYSES 
 
Antiretroviral Therapy Adherence 
 
Table A.1. Indicators of Antiretroviral Therapy Adherence: Descriptive Statistics 
 
Variable Mean Std Dev Min Max 
 
Perfect 
 
 
6.15 
 
1.52 
 
0 
 
7 
rForgot 
 
6.57 .90 0 7 
rSkip 
 
6.75 .91 0 7 
rLess 
 
6.70 .92 0 7 
Global 5.18 1.19 1 6 
 
 
Table A.2. Indicators of Antiretroviral Therapy Adherence:  
Varimax Rotation of Factor Loadings 
 
Variable Loading Uniqueness 
 
Perfect 
 
 
.86 
 
.27 
rForgot 
 
.63 .61 
rSkip 
 
.61 .62 
rLess 
 
.60 .63 
Global .70 .50 
 
 
  109 
Table A.3. Indicators of Antiretroviral Therapy Adherence:  
Item-Total and Inter-Item Correlations  
 
Variable Item-Total Inter-Item 
 
Perfect 
 
 
.88 
 
.40 
rForgot 
 
.72 .50 
rSkip 
 
.71 .51 
rLess 
 
.72 .50 
Global .78 .46 
 
 
Discriminatory Healthcare Experiences 
 
• Descriptive statistics for these dichotomous indicators are found in Chapter 5, Results. 
 
Table A.4. Indicators of Discriminatory Healthcare Experiences:  
Varimax Rotation of Factor Loadings 
 
Variable Loading Uniqueness 
 
Hostile 
 
 
.62 
 
.60 
LessAtten 
 
.64 .58 
Refuse 
 
.50 .75 
Uncomf 
 
.71 .49 
Inferior 
 
.75 .44 
Avoid .80 .36 
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Table A.5. Indicators of Discriminatory Healthcare Experiences:  
Item-Total and Inter-Item Correlations  
 
Variable Item-Total Inter-Item 
 
Hostile 
 
 
.76 
 
.06 
LessAtten 
 
.74 .06 
Refuse 
 
.62 .07 
Uncomf 
 
.76 .06 
Inferior 
 
.78 .06 
Avoid .80 .06 
 
 
 
Healthcare Provider Distrust 
 
Table A.6. Indicators of Healthcare Provider Distrust: Descriptive Statistics 
 
Variable Mean Std Dev Min Max 
 
Quality 
 
 
1.49 
 
.77 
 
1 
 
5 
Best 
 
1.50 .76 1 5 
Info 
 
1.54 .83 1 5 
Private 
 
1.34 .74 1 5 
NotJudge 
 
1.49 .81 1 5 
Insur 
 
1.53 .86 1 5 
Research 1.66 .93 1 5 
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Table A.7. Indicators of Healthcare Provider Distrust:  
Varimax Rotation of Factor Loadings 
 
Variable Loadings Uniqueness 
 
Quality 
 
 
.84 
 
.29 
Best 
 
.82 .33 
Info 
 
.83 .32 
Private 
 
.67 .54 
NotJudge 
 
.80 .35 
Insur 
 
.75 .43 
Research .77 .40 
 
 
Table A.8. Indicators of Healthcare Provider Distrust:  
Item-Total and Inter-Item Correlations 
 
Variable Item-Total Inter-Item 
 
Quality 
 
 
.85 
 
.41 
Best 
 
.83 .42 
Info 
 
.85 .40 
Private 
 
.73 .45 
NotJudge 
 
.84 .41 
Insur 
 
.81 .41 
Research .83 .40 
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Antiretroviral Therapy Attitudes and Beliefs 
 
Table A.9. Indicators of Antiretroviral Therapy Attitudes and Beliefs:  
Descriptive Statistics  
 
Variable Mean Std Dev Min Max 
 
Pills 
 
 
3.64 
 
.03 
 
1 
 
4 
Effect 
 
3.53 .06 1 4 
HIV 
 
3.64 .03 1 4 
Health 
 
3.78 .02 1 4 
Toxic 
 
3.59 .03 1 4 
Immune 
 
3.64 .02 1 4 
Holiday 
 
3.57 .04 1 4 
Depress 
 
3.57 .04 1 4 
Hard 
 
3.48 .03 1 4 
rEasy 
 
1.59 .04 1 4 
Time 
 
3.13 .04 1 4 
RunOut 
 
3.10 .03 1 4 
Away 
 
3.06 .05 1 4 
Busy 
 
2.96 .05 1 4 
Change 
 
3.23 .04 1 4 
Longer 
 
1.41 .02 1 4 
Improve 
 
1.64 .04 1 4 
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Table A.10. Indicators of Antiretroviral Therapy Attitudes and Beliefs:  
Varimax Rotation of Factor Loadings  
 
Variable Psychological 
Burden of 
Medication 
Difficulty 
Accessing 
Medication 
Difficulty 
Scheduling 
Medication 
Medication 
Efficacy 
Beliefs 
Uniqueness 
 
Pills 
 
 
.57 
 
-.04 
 
-.25 
 
-.06 
 
.61 
Effect 
 
.65 -.02 -.15 -.10 .55 
HIV 
 
.59 -.06 -.11 .00 .63 
Health 
 
.61 -.06 -.06 -.14 .60 
Toxic 
 
.73 -.06 -.11 -.13 .44 
Immune 
 
.64 -.09 -.11 -.04 .56 
Holiday 
 
.54 .01 -.25 -.12 .63 
Depress 
 
.66 -.07 -.21 -.04 .51 
Hard 
 
.11 -.60 -.01 -.11 .61 
rEasy 
 
-.11 .54 .00 .19 .65 
Time 
 
.09 -.57 -.18 -.07 .63 
RunOut 
 
.05   -.53 -.07 -.11 .70 
Away 
 
.23 -.11 -.60 .05 .57 
Busy 
 
.19 -.03 -.69 .03 .48 
Change 
 
.31 -.04 -.59 -.00 .56 
Longer -.12 .18 .01 .54 .66 
 
Improve -.19 .12 .04 .64 .54 
Note: These indicators are the final remaining after conducting a factor analysis on a set of 35 items. The strongest 
factor loading of the retained item is bolded. 
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Table A.11. Indicators of Psychological Burden of Medication:  
Item-Total and Inter-Item Correlations 
 
Variable Item-Total Inter-Item 
 
Pills 
 
 
.69 
 
.43 
Effect 
 
.72 .42 
HIV 
 
.65 .44 
Health 
 
.68 .43 
Toxic 
 
.76 .41 
Immune 
 
.71 .42 
Holiday 
 
.68 .43 
Depress .74 .41 
 
 
Table A.12. Indicators of Difficulty Accessing Medication:  
Item-Total and Inter-Item Correlations 
 
Variable Item-Total Inter-Item 
 
Hard 
 
 
.75 
 
.36 
rEasy 
 
.71 .40 
Time 
 
.75 .36 
RunOut .72 .38 
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Table A.13. Indicators of Difficulty Scheduling Medication:  
Item-Total and Inter-Item Correlations 
 
Variable Item-Total Inter-Item 
 
Away 
 
 
.83 
 
.50 
Busy 
 
.84 .46 
Change .80 .57 
 
 
• Medication Efficacy had two indicators, with an inter-item correlation of .56. 
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APPENDIX B: 
ATTRITION AND SELECTION BIASES 
 
Table B.1. Differences between Participants Who Did and Did Not Complete the Second 
Followup Interview: Bivariate Associations 
 
 
Completed  
2nd FU 
(n = 2267) 
% or Mean (SE) 
Did Not  
Complete 2nd FU 
(n = 597) 
% or Mean (SE) 
 
 
p 
 
Minority 
 
46.5 
 
57.3 
 
<.001 
 
Male Gender 
 
77.5 
 
77.3 
 
.940 
 
< 35 Years Old 
 
33.0 
 
36.7 
 
.171 
 
< High School Degree 
 
23.6 
 
28.6 
 
.225 
 
< $25,000 Annual Income 
 
69.4 
 
77.9 
 
.003 
 
Insurance in Last 6 Months 
     None 
     Medicaid 
     Medicare 
     Private 
 
 
17.6 
27.9 
19.8 
34.7 
 
 
17.7 
36.1 
20.6 
25.6 
 
 
.003 
 
Sexual Orientation 
     Homosexual 
     Heterosexual 
     Bisexual 
 
 
49.9 
42.1 
7.9 
 
 
41.2 
51.2 
7.7 
 
 
.018 
 
Risk Exposure 
     Injection Drug Use 
     Male-to-Male Sexual Contact 
     Male-to-Female Sexual Contact 
     Other 
 
 
23.4 
50.1 
18.5 
8.0 
 
 
28.2 
42.2 
15.0 
14.6 
 
 
<.001 
 
Year First Tested HIV+  
 
1991 (.07) 
 
1991 (.13) 
 
.051 
 
Has AIDS Diagnosis 
 
58.5 
 
66.9 
 
.006 
 
Depression Symptoms 
 
1.8 (.06) 
 
2.0 (.13) 
 
.168 
 
Dysthymia Symptoms 
 
.9 (.03) 
 
1.1 (.07) 
 
.019 
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Completed  
2nd FU 
(n = 2267) 
% or Mean (SE) 
Did Not  
Complete 2nd FU 
(n = 597) 
% or Mean (SE) 
 
 
p 
Used Heroin or Cocaine in Past Year 15.3 25.8 <.001 
 
Has Usual HIV Provider 
 
91.6 
 
89.6 
 
.210 
 
Perceived Social Support 
 
65.4 (.60) 
 
59.9 (1.23) 
 
<.001 
 
Discriminatory Healthcare 
Experiences 
 
1.2 (.04) 
 
1.3 (.14) 
 
.371 
 
 
Table B.2. Characteristics of Participants Who Completed the Second Followup 
Interview: Multivariate Associations 
 
 Completed 2nd FU 
(n = 2829) 
 OR (95% CI) p 
 
Minority 
 
.75 (.60, .94) 
 
.012 
 
Age 
 
1.07 (.99, 1.15) 
 
.103 
 
Annual Income 
 
1.04 (.93, 1.16) 
 
.519 
 
Medicaid 
 
.90 (.69, 1.16) 
 
.408 
 
Medicare 
 
.98 (.73, 1.31) 
 
.877 
 
Private Insurance 
 
1.12 (.77, 1.64) 
 
.534 
 
Heterosexual Orientation 
 
.77 (.50, 1.19) 
 
.230 
 
Bisexual Orientation 
 
1.02 (.70, 1.49) 
 
.932 
 
Injection Drug Use Risk Exposure 
 
1.04 (.68, 1.59) 
 
.851 
 
Male-to-Female Sexual Contact 
 
1.56 (1.01, 2.41) 
 
.047 
 
Other Risk Exposure 
 
.64 (.41, 1.01) 
 
.054 
 
Year Diagnosed HIV+ 
 
.98 (.95, 1.01) 
 
.266 
 
AIDS Diagnosis 
 
.68 (.52, .89) 
 
.006 
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 Completed 2nd FU 
(n = 2829) 
 OR (95% CI) p 
 
Depression Symptoms 
 
.99 (.95, 1.02) 
 
.495 
 
Dysthymia Symptoms 
 
.98 (.91, 1.05) 
 
.513 
 
Used Heroin or Cocaine in Past Year 
 
.87 (.79, .96) 
 
.008 
 
Social Support 
 
1.00 (1.00, 1.01) 
 
.009 
 
 
Table B.3. Differences between Participants Who Were and Were Not Prescribed 
Antiretroviral Therapy at the Second Followup Interview: Bivariate Associations 
 
 
On ART  
at 2nd FU 
(n = 1911) 
% or Mean (SE) 
Not on ART 
at 2nd FU 
(n = 356) 
% or Mean (SE) p 
 
Minority 45.7 51.1 .200 
 
Male Gender 
 
78.5 
 
71.8 
 
.023 
 
< 35 Years Old 
 
32.0 
 
39.1 
 
.023 
 
< High School Degree 
 
32.0 
 
39.1 
 
.001 
 
< $25,000 Annual Income 
 
67.3 
 
82.3 
 
<.001 
 
Insurance in Last 6 Months 
     None 
     Medicaid 
     Medicare 
     Private 
 
 
16.5 
27.1 
19.8 
36.7 
 
 
24.5 
33.0 
19.4 
23.1 
 
 
.002 
 
Sexual Orientation 
     Homosexual 
     Heterosexual 
     Bisexual 
 
 
50.4 
42.1 
7.5 
 
 
47.0 
42.6 
10.4 
 
 
.231 
 
Risk Exposure 
     Injection Drug Use 
     Male-to-Male Sexual Contact 
     Male-to-Female Sexual Contact 
     Other 
 
 
21.9 
51.4 
18.8 
8.0 
 
 
32.7 
42.7 
16.5 
8.1 
 
 
.003 
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On ART  
at 2nd FU 
(n = 1911) 
% or Mean (SE) 
Not on ART 
at 2nd FU 
(n = 356) 
% or Mean (SE) p 
 
Year First Tested HIV+  
 
1991 (.08) 
 
1991 (.18) 
 
.456 
 
Has AIDS Diagnosis 
 
60.8 
 
44.8 
 
<.001 
 
Viral Load  <1000 copies/ml 
 
43.0 
 
21.5 
 
<.001 
 
CD4 Count < 200  
 
27.2 
 
32.3 
 
.070 
 
Self-Perceived Physical Health 
 
50.1 (.22) 
 
47.5 (.61) 
 
<.001 
 
Self-Perceived Mental Health  
 
50.3 (.23) 
 
47.1 (.61) 
 
<.001 
 
Depression Symptoms 
 
1.8 (.07) 
 
2.2 (.17) 
 
.005 
 
Dysthymia Symptoms 
 
.9 (.03) 
 
1.2 (.09) 
 
<.001 
 
Used Heroin or Cocaine in Past Year 
 
14.4 
 
21.3 
 
.013 
 
Has Usual HIV Provider 
 
91.0 
 
90.0 
 
.241 
 
Perceived Social Support 
 
65.9 (.64) 
 
62.6 (1.58) 
 
.040 
 
Discriminatory Healthcare 
Experiences 
 
1.2 (.04) 
 
1.4 (.11) 
 
.124* 
 
Healthcare Provider Distrust 
 
1.5 (.01) 
 
1.8 (.05) 
 
<.001* 
*p value based on Wilcoxon rank sum test 
 
 
Table B.4. Characteristics of Participants Who Were Prescribed Antiretroviral Therapy at 
the Second Followup Interview: Multivariate Associations 
 
 On ART at 2nd FU 
 OR (95% CI) p 
 
Minority 
 
1.18 (.74, 1.89) 
 
.479 
 
Male Gender 
 
1.33 (.83, 2.14) 
 
.224 
 
Age 
 
1.06 (.97, 1.15) 
 
.172 
 
Education 
 
1.07 (.88, 1.31) 
 
.468 
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 On ART at 2nd FU 
 OR (95% CI) p 
 
Annual Income 
 
1.18 (1.02, 1.36) 
 
.028 
 
Medicaid 
 
1.26 (.74, 2.15) 
 
.384 
 
Medicare 
 
.99 (.61, 1.63) 
 
.980 
 
Private Insurance 
 
1.34 (.71, 2.52) 
 
.355 
 
Injection Drug Use Risk Exposure 
 
.97 (.57, 1.65) 
 
.904 
 
Male-to-Female Sexual Contact 
 
1.56 (.94, 2.60) 
 
.083 
 
Other Risk Exposure 
 
.99 (.48, 2.05) 
 
.986 
 
AIDS Diagnosis 
 
2.44 (1.44, 4.16) 
 
.001 
 
Viral Load 
 
.83 (.77, .89) 
 
<.001 
 
Lowest Ever CD4 Count 
 
.96 (.73, 1.25) 
 
.747 
 
Self-Perceived Physical Health 
 
.99 (.97, 1.01) 
 
.330 
 
Self-Perceived Mental Health 
 
1.01 (.99, 1.03) 
 
.188 
 
Depression Symptoms 
 
.96 (.92, 1.01) 
 
.092 
 
Dysthymia Symptoms 
 
.92 (.83, 1.02) 
 
.108 
 
Used Heroin or Cocaine in Past Year 
 
.93 (.86, 1.02) 
 
.107 
 
Social Support 
 
1.00 (.99, 1.00) 
 
.205 
 
Discriminatory Healthcare Experiences 
 
.95 (.87, 1.03) 
 
.205 
 
Healthcare Provider Distrust 
 
.58 (.47, .72) 
 
<.001 
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